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ABSTRACT

FLUOXETINE-SERT BINDING INTERACTIONS AND APO-SERT STUDIES VIA
CROSSLINKING MASS SPECTROMETRY

By
Elizabeth Castellano
August 2021

Dissertation supervised by Michael Cascio
The serotonin transporter (SERT) is a member of the neurotransmitter sodium
symporter family of transporters. SERT controls the magnitude and duration of
serotonergic neurotransmission by facilitating the reuptake of serotonin back into the presynaptic neuron and is thus a target for antidepressants. Selective serotonin re-uptake
inhibitors (SSRIs) such as fluoxetine, are commonly prescribed to treat depression. SSRIs
act by blocking reuptake and prolonging serotonin signaling. However, significant
problems regarding selectivity and mechanisms of action of these drugs remain unresolved.
The structures of SERT and related transporters have been determined and serve as useful
structural models. However, they are typically mutated for thermostability and typically
lack significant regions of the extracellular loops and the amino- and carboxy-termini and
are characterized in the absence of a native-like lipid bilayer. To further understand SERT
structure and the interactions involved in fluoxetine binding, herein we present two studies.
Aim 1 investigates fluoxetine binding sites of SERT using a photo-activatable fluoxetine
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analog and LC-MS/MS in crosslinking studies. Some of the crosslinks observed are
consistent with regions forming the central and allosteric sites in the crystal structure.
While other crosslinks are novel in that they are in areas of SERT that are unresolved such
as the terminal tails. Consistent crosslinks were observed on both N and C terminals,
suggesting that they are in close association with the lipid bilayer. Given that fluoxetine
partitions in bilayers and might interact non-specifically with membrane proteins, control
studies with photo-activatable lipids were also conducted to map lipid accessible sites.
Thus, allowing us to differentiate between specific and nonspecific fluoxetine binding. Aim
2 directly interrogates the topology of full-length SERT in lipid vesicles in its resting state
by coupling photoaffinity labeling with mass spectrometry (MS). The network of identified
crosslinks from introduced single cysteine mutants in the extracellular loops (EL) provides
distance constraints and topological information regarding SERT structure in the apo state.
Some identified crosslinks were consistent with the recently published crystal structure of
human SERT such as crosslinks between EL2 and EL4, which suggest proximity between
the two loops. Other crosslinks revealed novel structure information, such as consistent
crosslinks to the amino and carboxy terminal domains, thus suggesting that both terminal
tails are in close association with the lipid bilayer. Other novel structure information
includes modest movements in the N-terminus upon dimerization, and intermolecular
crosslinks in mutation S252C which suggest it is located near the dimer interface. Taken
together, the studies show that crosslinking mass spectrometry allows for the investigation
of local protein structure which can serve as a unique compliment to high resolution
structures and for which the benefits will bring us closer to the development of efficient
and improved therapeutics.
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Chapter 1: Introduction
1.1 Serotonin
Serotonin (5-hydroxytryptamine or 5-HT) is a monoamine neurotransmitter (Figure
1.1) that modulates the activity of the central nervous system. Serotonin is synthesized
from L-tryptophan, which is catalyzed by enzyme tryptophan -5-hydroxylase to form 5hydroxytryptophan, which is then converted to serotonin by L-amino acid decarboxylase
[2]. In serotonergic neurons, the end-product of the action potential is serotonin exocytosis
from pre-synaptic serotonergic neurons into the synapse where it interacts with serotonin
receptors, ligand-gated ion channels and a group of G-protein-coupled receptors in the
membrane of post-synaptic neurons to propagate the signal [1]. Dysregulation of 5-HT
concentration in the synapse is involved with a wide range of physiological functions such
as sleep, mood, appetite, cognition, pain, hunger, motor activity, aggression behavior and
hormone secretion [3].

Figure 1.1: Structure of monoamine neurotransmitter serotonin
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1.2 Serotonin Transporter
The serotonin transporter (SERT) is a member of the neurotransmitter sodium
symporter (NSS) family (also known as SLC6). The SLC6 family of proteins consists of
multiple proteins [4-7], however three stand out as a distinct family: the dopamine
transporter (DAT), norepinephrine transporter (NET), and the serotonin transporter
(SERT). DAT, NET and SERT all share structural and mechanistic properties [8]. They
utilize electrochemical gradients to transport their respective monoamine substrates from
the synapse to presynaptic neurons, against their concentration gradient [6]. SERT is
responsible for serotonin re-uptake [9] by coupling the entry of 5-HT to the entry of Na+
and Cl⁻ and the exit of K+ to move serotonin against its concentration gradient into presynaptic neurons [4, 10]. SERT follows an alternating access mechanism for ion/substrate
symport, wherein gates that open intracellularly and extracellularly do so in an alternating
fashion. Here, the ion flux is controlled by keeping one of the two gates always closed
(Figure 1.2). In the “alternating access” model, the transporter may be outward-facing,
occluded or inward-facing [11].

Outward
facing

Inward
facing

Figure 1.2 Alternating access model
The outward facing conformation allows for the entry of substrate and ions into the
binding site. The occluded conformation restricts binding pocket access. The inward
facing conformation allows for the release of substrate and ions inside the cell.
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Studies have revealed that the NSS family of proteins contain an inverted topology
repeat. SERT consists of 12 transmembrane (TM) domains with a pseudo-symmetry
arrangement of helices TM 1-5 and TM 6-10 with respect to the plane of the membrane
(Figure 1.3) [12] [11]. This pseudo 2-fold symmetry arrangement allows the ligand to enter
and exit the binding site thus creating a pathway for transport [13, 14].

Figure 1.3 Structural organization of NSS family of proteins
Pseudo-symmetrical arrangement of helices 1-5 and 6-10 depicted by inverted
blue triangles.

This inverted topology repeat is also observed across a variety of membrane
proteins including primary active transporters [15], secondary transporters [16], and
channels [17]. Bioinformatic studies have revealed that the pseudo-symmetry arrangement
is the result of an evolutionary pathway. Such studies provide evidence that protein
topology as we know it today, is the result of amino acid substitutions occurring over
evolution, as well as gene fusion, splicing, and deletion events [18].
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1.3 Resolved Structures of SERT and its Homologs
Historically, structure information of NSS proteins has been guided by studies on
the bacterial homolog Aquifex aeolicus leucine transporter (LeuT) and Drosophila
melanogaster dopamine transporter (dDAT). LeuT, has a 20-25% sequence identity to
SERT [14] and was crystallized by Dr. Yamashita and colleagues in 2005 [19]. LeuT has
been crystallized in three distinct conformations supporting the alternative access
mechanism [19, 20]. dDAT was crystallized bound to the tricyclic antidepressant
nortriptyline in 2013 [21]. Nortriptyline stabilizes dDAT in an outward-open conformation
by binding halfway across the membrane bilayer and blocking dDAT from adopting the
occluded state [21]. dDAT has a greater than 50% sequence identity with mammalian DAT
homologs and thus it has served as a powerful tool to understand SERT [21-23]. The
norepinephrine transporter (NET) is responsible for the reuptake of epinephrine from the
synapse to presynaptic neurons. There is currently no crystal structure of NET however
human NET, bovine NET and rat NET have been cloned and studied extensively [24-28].
In 2016, human SERT (hSERT) was crystallized bound to the antidepressant
citalopram [29]. Analogous to dDAT bound to nortriptyline, citalopram stabilizes hSERT
in an outward-open conformation with the antidepressant drug bound halfway across the
membrane bilayer. When bound to the drug, the conformations of TM1 and TM6 are
incompatible with the formation of the occluded state thus blocking SERT from adopting
the occluded state. The location of the allosteric site was also identified, interposed between
extracellular loops 4 and 6 and transmembrane helices 1, 6, 10, and 11.
In 2018, human SERT was crystallized bound to sertraline, fluvoxamine and
paroxetine [30]. The study revealed that all three antidepressant drugs bind to the central
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binding site and that they stabilize SERT in an outward-open conformation. The structures
also show that residues within the central binding site can adopt different conformations to
mediate selectivity. The study also revealed that a mutation at Thr 371 prevents closure of
the extracellular gate. Interestingly, this residue is equivalent to Thr356 in DAT, an autism
related mutation [30, 31].
In 2019, SERT-ibogaine complexes were captured in outward-open, occluded, and
inward-open conformations using cryo-electron microscopy (cryo-EM). The cryo-EM
structures revealed that ibogaine, a non-competitive inhibitor of transport, binds to the
central binding site and that TM1 and TM6 appear to undergo large movements during the
closing of the extracellular gate. Changes to TM1 were also observed during opening of
the intracellular gate along with partial unwinding of TM5 [32].
More recently in 2020, the structure of SERT bound to paroxetine analogs was
determined using single particle cryo-EM and x-ray crystallography [33]. The exact
binding pose of paroxetine in the central site is still a controversy. It is believed that the
central binding site is composed of three subsites: A, B, and C [34]. Some studies suggest
that paroxetine binds to SERT following an ABC pose mechanism. Here, the piperidine
ring binds to subsite A, while the benzodioxol group binds to subsite B and the
fluorophenyl groups bind to subsite C [29, 30]. Other studies suggest that binding occurs
following an ACB pose mechanism, where the benzodioxol group binds to subsite C, while
the fluorophenyl group binds to subsite B [35, 36]. It is believed that the ABC pose is
preferred over the ACB pose. However, the possibility that an ACB pose can still occur
has not been excluded.
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1.4 Selective Serotonin Reuptake Inhibitors (SSRIs)
SERT affects the magnitude and duration of the serotonergic signaling [37] and this
makes it a target for the development of antidepressants. Typical depression drug
treatments include tricyclic antidepressants (TCAs) and selective serotonin re-uptake
inhibitors (SSRIs). TCAs and SSRIs function by binding to SERT to inhibit re-uptake of
5-HT, thus extending serotonergic signaling [30]. As SERT is blocked, the relative 5-HT
concentration in the synapse increases (Figure 1.4). TCAs were among the earliest
developed antidepressants; they are highly effective, however they are not selective for
SERT and act on NET [38] and the acetylcholine receptor which can lead to serious
cardiovascular complications [39, 40]. SSRIs are among the most frequently used due to
their relatively high selectivity for SERT and limited off target receptors [28]. However,
despite SSRIs high selectivity, they can bind to the homologous transporters NET and
DAT, although with much lower affinity [24, 41].

Figure 1.4 SERT function
(A) Serotonin transporter (SERT) reuptakes serotonin from the synapse to the presynaptic
cell (B) SSRIs bind to SERT to block reuptake of serotonin causing an increase in serotonin
concentration in the synapse.
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SSRIs have varying chemical structures (Table 1.1) and as a result they possess
substantial pharmacological differences [42]. Paroxetine is the most potent SSRI with the
highest known binding affinity for the central binding site [43, 44] (Table 1.1). However,
paroxetine is associated with serious side effects such as infertility, cardiovascular issues,
birth defects, sexual dysfunction, and suicide [45]. Despite years of research,
antidepressants continue to carry serious side effects. Citalopram is associated with
insomnia, paroxetine with weigh gain, sertraline and fluoxetine cause gastrointestinal
problems, anxiety, insomnia. Fluvoxamine is associated with dangerous drug interactions
and highest frequency of gastrointestinal problems [46-49]. Fluvoxamine and paroxetine
have the highest discontinuation rates due to their side effects in clinical trials [50].

Table 1.1 Binding affinity of several SSRIs
Fluoxetine (Prozac) KD: 0.81nM, Ki: 1.1nM

Paroxetine (Paxil) KD: 0.13nM, Ki: 0.10nM

Sertraline (Zoloft) KD: 0.29nM, Ki:0.26nM

Citalopram (Celexa) KD: 1.16nM, Ki: 1.6nM

Equilibrium dissociation constant (KD) and inhibition constant (Ki) for various SSRIs
to human SERT. KD and Ki values adapted from Renoir (2013).
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Advances in molecular modeling has provided new pathways towards drug
discovery and design to improve today’s therapeutics. Wasko and co-workers [51]
developed computational methods for the purpose of designing new antidepressant drug
compounds. This approach utilizes fragment-based drug design methods in which small
fragments are introduced into the binding pocket (explained in more detail in section 1.6)
to serve as starting points prior to “growing” the drug candidate. This method offers a fast
and low-cost alternative for drug discovery. Nolan and co-workers [52] used a virtual
screening method followed by in vitro pharmacology studies to identify SERT inhibitors,
leading to the identification of an inhibitor with a modest affinity for hSERT (Ki = 284 nM)
and, proving that this approach is a powerful tool for identifying novel inhibitors.

1.5 Psychostimulants
SERT is not only the target for antidepressant medications but also
psychostimulants such as cocaine, ibogaine, and methamphetamine (Figure 1.5). Cocaine
is derived from the leaves of the Erythroxylum coca plant which is indigenous to South
America, Indonesia, Mexico and the West Indies [53]. Cocaine is a psychostimulant that
increases locomotor activity and euphoria sensation [54] by blocking SERT, NET and DAT
to prevent reuptake of their respective monoamines [55]. Cocaine stabilizes SERT in
outward-facing conformation [56]. In some cases, users experience paranoia episodes [57].
Cocaine can affect all body systems; among the most severe complications are seizures,
aortic dissection, hemorrhagic and ischemic strokes, acute renal injury, myocardial
infarction, and multiple organ failure [58]. Ibogaine is a natural occurring psychoactive
substance derived from the roots of the African plant Tabernanthe iboga [59]. Ibogaine
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can interact with numerous brain targets including glutamate receptors, nicotinic receptors,
and neurotransmitter transporters such as SERT [60, 61]. Ibogaine stabilizes SERT in an
inward-facing conformation [62]. Ibogaine has been reported to have anti-addiction
properties and has been used in patients with substance abuse disorders to reduce craving
and relapse rates [63]. However, evidence of the safety and efficacy of ibogaine in antiaddiction therapy is lacking. Clinical trials have shown that ibogaine is associated with
significant neurologic and cardiac effects such as cardiac dysrhythmias, seizures,
hallucinations, and depression [64] and, in some cases, sudden death [65].
Methamphetamine, unlike cocaine and ibogaine, is a man-made substance derived from
amphetamine [66]. Amphetamines were commonly used in the 1930s to treat a broad range
of disorders such as narcolepsy, depression, and behavioral problems in children (now
known as ADHD) [67-69]. Since then, amphetamines have transformed from easily
available drugs into highly restricted substances [70]. Methamphetamine is a highly
addictive substance that targets many areas in the brain with a high level of neurotoxicity
[71]. Studies examining the effects of methamphetamine have identified degeneration of
dopamine nerve fibers, loss of tyrosine hydroxylase, tryptophan hydroxylase, loss of
serotonin-immunoreactive axons and axon terminals [71-74]. At high levels,
methamphetamines can cause anxiety, hallucinations, psychosis, psychomotor impairment,
seizures, cerebrovascular hemorrhage, cerebral edema, myocardial infarction due to
heatstroke, and death [73, 75, 76].
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Ibogaine

Cocaine

Methamphetamine

Figure 1.5 Psychostimulants
Structures of psychostimulants that target SERT

1.6 SERT’s binding pockets
Prior to the crystallization of SERT, computational models were built to develop
the first structure based pharmacophores using the x-ray coordinates of LeuT [77-79].
Ligand docking experiments using cocaine and amphetamine models revealed potential
binding pockets [80], and suggested that the binding site for cocaine overlaps with the
binding site of dopamine in DAT [81]. DAT molecular modeling studies showed a ligand
binding pocket midway through the lipid bilayer, the S1 site [82]. Subsequent mutagenesis
and ligand docking studies revealed a second binding site, S2 for DAT located above S1
[79, 83].
The central S1 site is near the midpoint of the lipid bilayer and at the center of the
transmembrane domain, while the S2 allosteric site lies in the extracellular vestibule above
S1 [84]. Computational studies have suggested that S2 serves as an initial binding site
before substrate translocation to S1 via conformational changes [79]. The position of the
S1 binding pocket is supported by mutational analysis paired with structure-activity data
and drug affinity studies [85-87]. In addition, multiple antidepressants including SSRIs and
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certain TCAs have been shown to reach the S1 pocket [38, 88]. Computational studies
using the bacterial homolog LeuT, suggested that access to S1 is controlled by TM1-TM10
ionic interactions and TM3-TM6 hydrophobic bridges [84]. hSERT bound to citalopram
was crystallized in 2016 by Coleman et al. [29] and it was observed that hSERT exhibits
an outward-open conformation with the drug bound to the central site, halfway across the
membrane lodged into a cavity consisting of residues from TM1, TM3, TM6, TM8 and
TM10, with the location of the allosteric site located between EL4 and 6 and TM helices
1, 6, 10 and 11.

1.7 Effects of lipid composition
Lipid composition can greatly affect activity of membrane proteins, and they can
modulate transmembrane proteins through a variety of interactions: hydrogen bonding,
charge interactions, hydrophobic interactions, altering membrane fluidity, etc. [89].
Multiple studies have shown evidence of lipid interactions with SERT. For instance,
studies by Magnani et al. show that SERT associates with lipid rafts and that disaggregation
of lipids rafts inhibits SERT activity [90]. In addition, computational studies have
suggested that phosphatidylinositol 4,5-biphosphate (PIP2) interact with the terminal tails
of the transporter [91]. It is known that lipid interaction is important for activity, but
specific sites of interactions are yet to be revealed.
In addition, lipid composition is of great interest for its role on oligomeric state.
There is growing evidence that SERT forms a broad distribution of oligomerization ranging
from monomers up to pentamers [92, 93]. Single-molecule fluorescence microscopy
studies have shown that stabilization of SERT oligomeric complexes are mediated by direct
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interactions to phosphatidylinositol-4,5-biphosphate (PIP2) [92]. Thus, it is essential to
conduct studies of SERT in a complete and functional state to fully understand SERT-drug
binding sites and structure, and CX-MS allows us to conduct such studies.

1.8 Chemical protein modifications
Chemical modifications of proteins are common in cells and play key roles in
cellular processes such as trafficking, differentiation, signaling and migration [94]. The
reproduction of chemical modifications of proteins in a highly efficient and controlled way
has proven to be an invaluable tool in proteomics. Classic protein modification methods
rely on reactions with nucleophilic amino acids such as cysteine and lysine residues. Prior
to the elucidation of SERT structure by x-ray crystallography, Chen and coworkers [10]
mapped the reactivity of three cysteine residues predicted to be in the extracellular surface
of SERT using methanethiosulfonate (MTS) reagents and site-directed mutagenesis. MTS
reagents react with free cysteine residues and form a disulfide between the cysteine sulfur
and the reagent. Hence, if the cysteine residue were reactive the modification could alter
normal protein function. However, if the cysteine were inaccessible, no functional changes
would occur. The results of this study predicted the disulfide bond between C200 and C209
in the second extracellular loop. In later years, Androutsellis-Theotokis and coworkers [95]
examined cysteine residues in the internal surface of SERT that were responsible for the
inactivation of 2-β-carbomethoxy-3-β-(4-[125I]iodophenyl)tropane (β-CIT) binding, a high
affinity cocaine analog, by MTS reagents in membrane preparations. For this study, a
mutant SERT was prepared (X8C), in which eight active cysteines were replaced by other
amino acids (at positions 15, 21, 109, 147, 155, 357, 522, and 622), while retaining
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significant binding activity and transport. X8C was further modified by restoring each
mutated cysteine back into the construct. HeLa cells expressing SERT were assayed for
serotonin transport activity or β-CIT binding activity with or without 2-(aminoethyl)
methanethiosulfonate hydrobromide (MTSEA). The transport and binding activities of all
mutants was assayed. X8C retained 31.9 ± 3.8% transport activity and 55.8 ± 6.3% binding
activity. The results of the study showed that C357 at the third intracellular loop is a
reactive cysteine and that it is sensitive to conformational changes resulting from ligand
and ion binding.

1.9 Photo-crosslinking coupled with tandem mass spectrometry
1.9.1 Crosslinking
Structure determination of proteins and identification of protein-protein
interactions (PPI) are key to understanding protein function [96]. PPI maps can provide a
framework for better understanding all biological systems as it serves as a “skeleton” for
its signaling circuitry [97]. Molecular chaperone proteins are an example of a multicomplex assembly where several components work in a coordinated matter to assist in
protein folding [98]. For decades, crosslinking methods have been used to study PPI and
protein structure [99, 100]. Under physiological conditions PPI are short lived and hence
are difficult to study. Crosslinking allows for this short-lived reaction to be captured by
covalently binding them together for subsequent characterization [101, 102]. Despite the
high complexity of proteins, only a small number of functional groups account for the
majority of targets in crosslinking methods: primary amines, carboxyls, carbonyls, and
sulfhydryls (thiols) [103].
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Crosslinking studies can be performed in vivo or in vitro. For in vitro crosslinking,
cells are homogenized and lysed. In vitro crosslinking studies on chaperone proteins have
revealed how chaperones interact with proteins, and protein complexes to assist in protein
folding [104, 105]. For in vivo crosslinking, proteins are crosslinked inside the cell.
Freinkman et al. conducted in vivo crosslinking studies to obtain insight into protein
interactions in Gram-negative bacteria [106]. Lipopolysaccharides are transported to the
outer membrane of gram-negative bacteria, but the process was poorly understood.
Freinkman et al. used unnatural amino acid mutagenesis and crosslinking to show that
LptD and LptE interact. They introduced a UV-photocrosslinker para-benzoyl-Lphenylalanine at 27 positions throughout LptE, and subsequent UV light exposure of living
cells captured LptE-LptD interactions.
Formaldehyde crosslinking can be used to crosslink DNA-binding proteins to DNA
in vivo and in vitro [107, 108]. However, although the chemistry for formaldehyde
crosslinking is well known, the in vivo aspects behind the technique are still not fully
understood [109]. Nevertheless, it has been shown to successfully crosslink accessible
lysine residues, making it a crosslinker of choice for trapping protein-DNA complexes due
to lysine residues being common mediators of interactions with DNA [110].

1.9.2 Mass Spectrometry
Major advances in mass spectrometry has transformed this instrument into an
indispensable tool for scientists in proteomics research and their efforts to characterize
cellular function [111, 112]. Mass spectrometers consist of an ion source that converts
analyte molecules into gas-phase ions, a mass analyzer that sorts ionized analytes according
to their mass to charge ratio (m/z) and a detector that records the ions [111]. Finally a “mass
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spectrum” plot is generated which comprises of ion abundance against m/z [113]. Mass
spectrometry (MS)-based proteomics can be performed on intact protein (top-down
proteomics) or on digested peptides (bottom-up proteomics), with each method having
their own advantages and disadvantages [114]. In general there are 4 stages: protein
preparation, chromatographic separation, mass spectrum of peptides is recorded and, a list
of peptides is generated [115].
In proteomic research, soft ionization methods are commonly employed such as
electrospray ionization (ESI) and matrix-assisted laser desorption/ionization (MALDI)
[116, 117]. In MALDI, the analyte is embedded into a UV absorbing matrix, upon
radiation by a laser pulse, an analyte-matrix mixture is produced, and vaporization of the
matrix carries the analyte with it [118]. In ESI, the analyte is in solution. The volatile liquid
is emitted towards an electrode under vacuum, upon solvent evaporation, the drop then
decreases in volume producing smaller droplets and finally results in charged ions entering
the gas phase [117]. Once the analyte is ionized, ions are separated according to their m/z
ratio by the mass analyzer, commonly a quadrupole, time of flight, or orbitrap [119]. In
tandem MS, a collision cell is incorporated for fragmentation.
Fragmentation techniques include collision-induced dissociation (CID), electron
capture dissociation (ECD), and electron transfer dissociation (ETD) [120]. CID is the most
common fragmentation technique employed in the study of peptides and proteins [121]. In
CID, precursor ions collide with neutral gas molecules causing bond cleavage and product
ion formation [122]. Typically, breakage occurs through the lowest energy pathway at the
amide bond, producing “b” and “y” ions ( defined as a “b” ion if the charge is at the amino
terminal fragment, or “y” if the charge is at the carboxy terminal fragment). In addition,
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“a” ions can be formed upon fragmentation (cleavage between the alpha and carbonyl
backbone carbons), though this occurs less frequently than by and y ion products (Figure
1.6) [123].

Figure 1.6 Peptide fragmentation pattern via collision induced dissociation.
CID typically forms “b”, “y” ions and, though less occurring, “a” ions.
Mass analyzers commonly used in proteomics are the quadrupole, the ion trap, and
time-of-flight (TOF) [111]. They vary in their physical principles and performance. The
quadrupole consists of four parallel rods, one pair applies radio frequency (RF) voltage
while the other pair applies direct current (DC) voltage. Inside the quadrupole RF and DC
voltages are combined and at a given combination ions of a particular m/z ratio are allowed
to travel through the quadruple into the detector while other ions collide against the rods
and don’t reach the detector [124]. A linear series of three quadrupoles is known as the
triple quadrupole mass spectrometer, where the first and third quadrupoles are used as
filters while the second quadrupole is used as a collision cell. The triple quadrupole is an
efficient tool for tandem mass spectrometry.
Ion traps utilize oscillating electric field to “trap” ions. There are different types of
ion traps such as linear ion trap (LIT), Fourier transform ion cyclotron resonance (FT-ICR),
and orbitraps [125]. LIT consist of a quadrupole with hyperbolic rods cut into three
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segments. It can be used as mass filter or as a trap. To operate as a trap, the rods apply RF
voltage and the electrodes of slightly higher potential located at both ends create a trapping
potential well that prevents ions from escaping [126]. To operate as an analyzer, the rods
apply a DC voltage to create an axial trapping field, RF voltage is supplied to deliver a
radial trapping field, and AC voltage is applied for ion isolation, activation and ejection
[127]. Linear ion traps are also capable of precursor ion selection for tandem MS
experiments. FT-ICR mass spectrometers consist of an ICR cell composed of two trapping
plates, two excitation plates, and two detector plates arranged in a cube-like shape and
surrounded by a strong magnetic field [128]. Superconducting magnets are used to provide
a strong magnetic field, thus making FT-ICR the most expensive mass spectrometers by
far. Ions affected by the magnetic field move in an orbital motion known as “cyclotron
motion” and the frequency of this motion is inversely proportional to the m/z ratio of the
ion. As the RF voltage is applied, ions accelerate bringing them closer to the detector plates.
The image current is then deconvoluted by Fourier transformation and the m/z ratio is
determined [128, 129]. Orbitraps are the newest type of mass analyzers that use Fourier
transformation technology, and it was invented by Dr. Makarov in 1999 [130]. The orbitrap
consists of an outer barrel-like electrode and an inner spindle-like electrode. Voltage is
applied between the electrodes creating an electric field that traps ions in an orbital motion
around the central spindle. Mass to charge values are measured from the frequency of
harmonic ion oscillations by Fourier transformation [131].
Time-of-flight (TOF) mass analyzers separate ions based on the time it takes for
them to travel through a flight tube. Ions are accelerated by an electric field into the flight
tube. Here all the ions start to travel through the flight tube at the same time with the same
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kinetic energy but reach the detector at different times due to their masses. Essentially,
lighter ions will arrive to the detector first then the heavier ions [132]. The first TOF mass
analyzers were linear and though they offered fast scan rates and an unlimited m/z limit,
the resolution was poor. TOF analyzers greatly improved with the incorporation of
“delayed extraction” of ions leaving the source, and reflectrons which correct the initial
energy spread, hence increasing resolving power [133]. To enhance performance, “hybrid”
instruments have been designed. For instance, early quadrupole mass analyzers were
capable of only unit resolution, but the coupling of quadruple and time-of-flight (QTOF)
analyzers provide higher resolution up to 0.01 Da [129].

1.9.3 Crosslinking Mass Spectrometry (CX-MS)
CX-MS offers the capability of analyzing three-dimensional structure of proteins
and mapping protein-protein interactions [134]. Over the years, many types of crosslinkers
have been developed. Conventional crosslinking reagents contain two reactive sites
connected through a spacer, typically an alkyl chain [135, 136]. Homobifunctional
crosslinkers contain identical functional groups at both reactive sites. Whereas
heterobifunctional crosslinkers contain two different reactive groups that target different
functional groups. The amine-reactive N-hydroxysuccinimide (NHS) ester crosslinker
reacts with nucleophiles to release the NHS and create a stable amide with primary or
secondary amines. NHS esters have successfully been used to probe structure of proteins
in living cells [137]. Maleimides are sulfhydryl-reactive cross-linkers with little activity to
amines thus making them valuable for intramolecular crosslinks [138]. Photoreactive
crosslinkers react with their target by exposure to UV light [139]. This tool has been widely
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used in drug discovery to identify drug targets, molecular interactions, and for probing
binding sites [140]. This is particularly useful in that it can convert short lived interactions
between molecular target with a drug candidate into permanent bonds [141].
Benzophenone photoprobes can be activated at safe wavelengths of 350-360 nm, which
cause no harm to proteins, and can react in the presence of water and bulk nucleophiles
thus making them highly efficient [142]. Benzophenones create a biradical upon UV
exposure, which undergoes a hydrogen radical abstraction and form a new C-C bond [136].
Currently, there is a library of crosslinkers available that vary in spacer length and reactive
groups. Some crosslinkers contain groups used as purification or detection handles [143145]. Young et al. [146] used an amine specific homobifunctional crosslinker
(bis(sulfosuccinimidyl) suberate) to probe the tertiary structure of bovine fibroblast growth
factor protein. Lysine residues were crosslinked, trypsinized, and analyzed using HPLCQTOF-MS and MALDI. The study generated distance constrains that allowed for the
refinement of protein models. Analysis of crosslinked peptides by mass spectrometry offers
several advantages such as: (1) unlimited protein/protein complex mass because it is the
proteolytic peptides that are analyzed, (2) fast analysis, (3) only requires small amounts of
sample, (4) the broad range of crosslinking reagents offer varying specificities towards
certain functional groups, and a wide range of distances [136]. Advances in
chromatography separation and sample enrichment methods has made the study of low
abundant crosslinked peptides, compared to unmodified peptides, by crosslinking mass
spectrometry (CX-MS) a popular tool in proteomics [99, 147-149]. Recently, CX-MS has
found to be suitable for the analysis of an array of in vivo and in vitro applications of not
only large protein complexes but also at the proteome scale [150].
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Crosslinking experiments have been used to study not just protein-ligand
interactions but also allosteric modulation in proteins and oligomerization [151-153].
Protein dynamics and allostery are difficult to study using high resolution structure
methods like crystallography due to their dynamic nature. However, the integration of
crosslinking with the high sensitivity, high mass resolution and high mass accuracy
advantages in mass spectrometry has emerged CX-MS as a powerful tool in proteomics
[154]. CX-MS can serve as a complementary tool to high resolution structure studies and
in modeling dynamic regions of proteins. For example, Liu et al. analyzed intra- and intersubunit crosslinks of trypsinized peptides by MALDI-TOF MS to study the extracellular
domain of the glycine receptor [155]. The crosslinking constraints were used to validate
and refine allosteric models. CX-MS has also proven to be an essential tool in
pharmaceutical chemistry. CX-MS studies have been used to probe allosteric changes due
to protein-drug interactions [156]. The coupling of crosslinking with mass spectrometry
provides advantages that provide insights into complete systems with great degree of detail
and sensitivity in a timely manner [157].
CX-MS has also proven to be useful when studying complex post-translational
modifications (PTMs). Chavez et al. [158] utilized CX-MS to obtain topology
measurements on post-translationally modified histone proteins in vivo. Proteins on HeLa
cells were crosslinked with BDP-NHP-PIR crosslinker which contains a biotin affinity tag
for enrichment purposes, and two CID cleavable bonds to release cross-linked peptides.
Crosslinked peptides were then trypsinized and analyzed using a UPLC coupled with
FTICR Ultra hybrid mass spectrometer. In the study, 115 crosslinks were detected, for
which 56 were found to contain at least one post-translational modification. Their results
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shine a light into the topology of core histone protein H3 as it is altered with varying PTMs.
For instance, some crosslinks were only observed when protein was unmodified, while
other residues were only crosslinked when protein was modified by mono-, di-, or trimethylation. Unique crosslinks were also observed when histone H3 was modified by
acetylation. The information provided by this study brought to light the structure and
orientation of nucleosome complexes in vivo.
Affinity-tagged crosslinking reagents have been developed to allow for purification
of proteins of interest and enrichment of low abundant crosslinked peptides. Biotin-tagged
crosslinkers allow for the isolation of peptides by avidin affinity chromatography [159].
Other affinity-tagged crosslinker reagents include azide-containing crosslinkers, which can
be isolated using “click chemistry” [160].

1.10 Rationale
Historically, x-ray crystallography has been widely used to determine protein
structure, the atomic details offered by this technique has proven it to be powerful tool to
understand chemical details and function [161, 162]. However, this technique does not
allow for an investigation of complete protein system. In many cases, proteins are
mutagenized and truncated to achieve the thermostability required for crystal formation.
The crystal structure of hSERT has served as a useful tool for further understanding SERT
function and its drug-binding sites. However, it lacks significant regions of the extracellular
loops and the amino- and carboxy-termini which needed to be truncated for thermostability
(see Table 1.2). These regions cannot be ignored for they are believed to have functional
importance. The external loop regions are suggested to be involved in conformational
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changes required for transport [163]. Furthermore, the N-terminus has been shown to be
an allosteric modulator of hDAT [91, 164, 165]. A study showed that amphetamineinduced substrate efflux is obstructed when the N-terminal of SERT is tethered to the
membrane [166], thus suggesting that the N-terminal is flexible and may be required for
conformational rearrangements during transport. The C-terminus of SERT has shown to
interact with the first intracellular loop to facilitate folding [167]. Furthermore, several
proteins that interact with SERT’s N and C termini have been identified [7], demonstrating
that these regions are essential for regulation. These proteins include Sec24C which binds
to the C-terminal domain of SERT [168, 169], and syntaxin 1A which interacts with the
N-terminal domains of SERT, DAT and NET [170-172]. In addition, crystallographic
studies are also conducted in membrane-mimetic environments and the structure of the
transporter may be affected by the lipid bilayer [173]. In our study we use complete SERT
protein with no truncations in lipid vesicles to preserve membrane-like environment.
In the development of specific and effective antidepressants it is vital to understand
SERT activity and function. To fully understand SERT, it is necessary to investigate all its
conformational states. Currently, there is no information available about the structure of
SERT in the apo state. The current crystal structure of hSERT exhibits an outward-open
conformation, it has not been crystallized in the apo state. Investigating the apo state is
crucial because it will help us understand where allosteric changes occur as it transitions
from resting state to an outward-open conformation with the drug bound. The development
of efficient therapeutics depends on a full understanding of the target protein. This led us
to investigate SERT in the apo state. Although the loops are known to have physiological

22

importance [10, 167], their topology is not fully characterized. Hence in this study we
investigated SERT in its entirety without any truncations.

Table 1.2 SERT structures to date.
Allosteric
State

Method

Resolution

(S)citalopram
or
paroxetine
in Fab
complex
Sertraline or
fluvoxamine
or
paroxetine
in Fab
complex
Ibogaine in
Fab complex

X-ray
crystallo
graphy

3.15 Å

X-ray
crystallo
graphy

3.5 Å, 3.8Å

Cryo-EM

3.6Å, 4.1Å,
and 4.2Å

Cryo-EM
and x-ray
crystallo
graphy

3.3Å (cryo)
6.3Å (xray)

Paroxetine
in Fab
complex

Alterations

Activity

Mutations: I291A,
No detectable
T439S, Y110A,
transport activity
C554A, C580A,
C622A. (Residues
1-76 and 618-630
truncated)
Mutations: Y110A,
No detectable
I291A, T439S,
transport activity
C554A, C580A,
C622A. (Residues
1-76 and 618-630
truncated)
Mutations: C109A,
Transport
C147A, C155A,
competent
C166L, C522S,
C357L, C369L,
I291A, T439S,
Y110A, I291A.
(Residues 1-72 and
617-630 truncated)
Mutations:
Cryo-EM
C109A, C147A,
structure is
C155A, C166L,
transport
C522S, C357L,
competent; no
C369L, I291A,
transport activity
T439S, Y110A,
in the x-ray
I291A. (Residues
crystal
1-72 and 617-630
truncated)

Year &
PDB Code
2016
PDB Code:
5I71

2018
PDB Code:
6AWO

2019
PDB Code:
6DZZ

2020
PDB Codes:
6VRH and
6W2C

1.11 Limitations of the study
A limitation of this study is that the peak intensities in mass spectrometry reflect
the relative ionization of the mass ions, not their concentration. Hence, the relative
abundance of the crosslinks cannot be determined. Quantification of the crosslinks would
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differentiate high probability events from low probability events, thus further refining
protein-protein interactions. To address this problem, we propose to implement a laserinduced fluorescence microfluidic platform to quantify mass shifted peptides.
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Chapter 2: Methodology
2.1 SERT-Fluoxetine Interactions Study
Rat SERT (rSERT)
rSERT plasmid amplification and purification- Blotted rSERT cDNA on filter paper in
pBlueScript plasmid (X8C) was kindly provided by Dr. Gary Rudnick from Yale
University School of Medicine. The blotted filter paper was resuspended in deionized water
and vortexed to extract DNA from the filter paper. The plasmid DNA was transformed and
introduced into XL-1 Blue competent cells. Transformation was achieved by heat shock in
a water bath for 30 seconds at 42°C, 2 minutes ice incubation, followed by recovery in 0.5
mL of super optimal broth with catabolite repression (SOC) media for 1 hour with gentle
shaking at 37°C. Cells were plated overnight on Luria Broth (LB)- amp plates (0.1 mg/ml
ampicillin antibiotic) at 37°C overnight. After overnight growth, single colonies were
collected and grown overnight in 2 mL of LB-amp growth media (0.05 mg/ml ampicillin
antibiotic) with shake incubation at 37°C and 225 rpm. After overnight growth, the plasmid
DNA was extracted and purified by miniprep using UltraClean Standard Mini Plasmid Prep
Kit following the manufacturer’s instructions.
Plasmid X8C in pBlueScript and pFastBac expression vector were digested with
Sal1 and Xba1 at 37°C for 1 hour. Next the restriction enzymes were inactivated at 65°C
for 20 minutes. Digested pFastBac was treated with FastAP thermosensitive alkaline
phosphatase to prevent re-ligation of the vector. Next the digested X8C and pFastBac were
run on an 8% agarose gel to separate the DNA pieces. Gel plugs containing X8C insert at
the 2 kilo base pair (kbp) region and pFastBac at the 4.7 kbp region were isolated and
purified using Ultra-Sep gel extraction kit by Omega. Next, pFastbac and X8C were ligated
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together overnight at different insert to vector ratios (1:1, 2:1, and 3:1) at 16°C. Ligated
DNA was transformed into DH-10 competent cells and colonies were grown in LB-agar
plates containing 0.1 mg/mL of ampicillin. After overnight growth, single colonies were
collected and grown in 2 mL of LB media. Next, the plasmid DNA was extracted and
purified using UltraClean Standard Mini Plasmid Prep Kit by MO Bio Laboratories.
Purified DNA was then sequenced to verify the presence of cDNA rSERT insert in
pFastBac vector.
Production of rSERT Recombinant Virus- Recombinant plasmid DNA was transformed
into XL-1 Blue competent cells. Correct orientation of X8C was confirmed by DNA
sequencing (GeneWiz). Transformation of recombinant pFastBac in DH10Bac
(Invitrogen) competent cells was performed using the manufacturer’s instructions. Briefly,
transformation was performed by heat shock in a water bath at 42°C for 45 seconds
followed by ice incubation for 2 minutes. Next, cells were shake incubated in 900 µl of
SOC growth media for 4 hours at 37° C and 225 rpm. Cells were serially diluted by a factor
of 10 and each dilution was plated on Luria agar plates containing 50 µg/ml kanamycin, 7
µg/ml gentamicin, 10 µg/ml tetracycline, 100 µg/ml Bluo-gal, and 40 µg/ml isopropyl βd-1-thiogalactopyranoside (IPTG). DH10Bac competent cells contain a helper plasmid and
a bacmid. Bacmid holds a mini-Tn7 target site and the helper plasmid provides the needed
transposition proteins for site-specific transposition from pFastBac into bacmid to take
place. The insertion of rSERT in the bacmid results in the disruption of the LacZ operon,
which codes to produce β-Galactosidase, this enzyme catalyzes the hydrolysis of lactose
into glucose and galactose. Detection of the colonies containing recombinant bacmid was
accomplished using the blue-white screening method. Here, if the Lac-Z operon is
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functional and not disrupted by a transposed gene, then IPTG will promote the production
of β-Galactosidase by the LacZ operon, which hydrolyzes X-gal into 5-Bromo-4-chloro-3hydroxyindole and galactose. 5-Bromo-4-chloro-3-hydroxyindole then oxidizes into 5,5’dibromo-4,4’-dichloro-indigo, which is blue in color. The colonies formed by nonrecombinant cells will therefore appear blue in color while the recombinant bacmid cells
will appear white in color. Plates were incubated at 37°C for ~40 hours. Single white
colonies containing recombinant bacmid were inoculated into 2 ml of LB media containing
50 µg/ml kanamycin, 7 µg/ml gentamicin, 10 µg/ml tetracycline and incubated at 37°C
with overnight shaking at 250 rpm. Bacmid DNA was extracted and purified. Briefly,
growth media was removed by centrifugation at 13,000 g for 2 minutes. Next 300 µl of
resuspension buffer (50 mM of Tris-HCl pH 8, 10 mM ethylenediaminetetraacetic acid
(EDTA), and 200 μg/mL RNase A) was added to the pellet and cells were suspended until
homogeneous with no vortex. Next 300 µl of cell lysis solution (200 mM NaOH, 1% SDS)
was added and mixed gently by inverting. Tubes were incubated at room temperature for 5
minutes. Samples were neutralized by adding 300 µl of 3 M potassium acetate pH 5.5 and
mixed by inverting the tubes 5 times. Samples were subsequently incubated on ice,
harvested, and suspended in absolute isopropanol at -20°C overnight. Samples were
centrifuged, and supernatant was removed. Pellets were washed with 70% ethanol and air
dried. Finally, the bacmid was resuspended in 40 µl of Tris-EDTA (TE) buffer pH 7.5 (1
M Tris, 0.5 M EDTA)
Isolation of recombinant baculovirus- Sf9 cells were purchased from Thermo Fisher
Scientific. A frozen vial of Sf9 cells at a concentration of 1x107 cells/ml was quickly thawed
in a 37°C water bath until only a small frozen piece remained. The vial was then
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decontaminated, and cells were transferred into a cell culture flask containing 25 ml of
complete media, Grace’s Insect Medium (Gibco) supplemented with 10% fetal bovine
serum (FBS) (Gibco) and 100 ug/ml penicillin-streptomycin (Gibco). Cells were incubated
at 27°C for 45 minutes to allow for cell attachment, and the media was aspirated and
replaced with fresh media. Sf9 cells double every 18-22 hours and at 90-100 percent
confluence they were transferred into a 100ml spinner flask. For transfection trials, Sf9
cells were seeded at 1 x 106 cells/ml on a 35 mm well in 2 ml of complete media. Cells
were then stored at 27°C for at least 1 hour to allow for cell attachment. Next, the media
was replaced with fresh non-complete Grace’s media (no FBS and no antibiotics). 800 ul
of non-complete Grace’s media was added to a CellFectin/bacmid DNA mixture (1 µg
Bacmid DNA in 100 µl non-complete Grace’s media, and 6 µl of cationic lipid transfection
reagent Cellfectin in 100 µl of non-complete Grace’s media) and 160 µl of the
CellFectin/bacmid DNA/Grace’s media mixture was added into each well and incubated
for 5 hours at 27°C. CellFectin lipid solution assists bacmid DNA cross the cell membrane
of the Sf9 cells. After 5 hours, the media was replaced with fresh complete media and stored
for 72 hours at 27°C. After the transfected Sf9 cells showed late-stage infection phenotypes
(viral budding, lysis), the media containing amplified virus was harvested after pelleting of
intact and dead cells by centrifugation at 500 x g for 5 minutes. The baculovirus was later
amplified by infecting 800 ml of cells at 1 x106 cells/ml with virus in a ProCulture spinner
flask. Cells were incubated in a 27°C, non-CO2, non-humidified incubator on a spinner
platform with gentle swirl for a week. The concentration of viral particles was determined
with a viral titer plaque assay.

28

Viral Titer Assay- Titer assay was performed in a sterile 96 well plate. 12 wells
were plated with 100 µl of cells at 3x105 cells/ml and incubated at 27°C for 30 minutes to
allow cell adherence. Five dilutions of virus were prepared (10 -2, 10-4, 10-5, 10-6, and 10-7)
by adding 990 µl of Grace’s media to tube 10-2 and tube 10-4 and 10 µl of virus stock to 102

. Next, 10 µl of the 10-2 tube was transferred to tube 10-4. Then 100 µl of the 10-4 and 900

µl of Grace’s media were added to tube 10-5. The remaining dilutions were prepared by
serial 10-fold dilutions. The media was removed, and every 2 wells was infected with 100
µl of each virus dilution, leaving the 1st and 2nd wells as control (no infection), and was
incubated for 1 hour at room temperature. Afterwards, the supernatant containing virus was
removed and 200 µl of Grace’s media was added to each well. The plate was placed in a
sealed bag with a wet paper towel to prevent evaporation of the medium and incubated for
24-30 hours at 27°C. The media was then removed, and wells were washed twice with 100
µl of PBS (0.01 M pH 7.2) for 1 minute each. Next the cells were washed a third time with
100 µl of 4% paraformaldehyde. Plates were incubated for 30 minutes at room temperature
followed by final rinse with 100 µl of PBS (0.01 M pH 7.2). The cells were then blocked
with 100 µl of a blocking buffer (5% normal goat serum (NGS), 0.05% polysorbate 20
(Tween), in PBS) for 30 minutes at room temperature. Wells were then washed with 100
µl of wash buffer (1% NGS, 0.05% Tween in PBS for 1 minute. Next, 50 µl of primary
antibody solution mouse α GP64 (monoclonal antibody that reacts with the gp64 envelope
protein of baculovirus) (Abcam) diluted 1:1000 in PBS containing 5% NGS, and 0.05%
Tween) was added to each well and plate was incubated for 1 hour at room temperature.
Wells were washed three times with wash buffer for 1 minute each wash. Next, 50 µl of
secondary antibody solution (goat anti-mouse conjugated to β-Galactosidase diluted
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1:1000 in PBS, containing 1% NGS, and 0.05% Tween) (Calbiochem) was added to each
well and incubated for 1 hour at room temperature. Wells were then washed three times
with wash buffer. Next 50 µl of coloring solution (4 µl of 50 mg/ml X-gal in
dimethylformamide (DMF)), 4 µl of 83 mg/ml p-nitroblue tetrazolinium in DMF, 5 mM
MgCl2 in 1 ml of PBS was added to each well and plate was incubated at 37°C until cells
appeared medium blue to dark purple under light microscope (~2 hours). Once color was
established, reaction was stopped by washing three times with PBS. Strongly stained
individual cells or cell clusters were counted as 1 unit. Viral titer was determined using the
following formula: Titer (pfu/ml) = 10 x (# of infected units) x (viral dilution factor)
rSERT overexpression- A 3L Corning ProCulture spinner flask containing 800 ml of Sf9
cells at a concentration of 1x106 viable cells/ml was infected with virus at a multiplicity of
infection (MOI) greater than 5 at 27°C for 3 days. MOI was calculated using the formula
below. Cells were harvested 3 days post infection by centrifugation at 500 x g for 5 minutes.
Inoculum required (ml):

pfu
)x
ml

desired MOI (

total number of cells
pfu
)
ml

𝑡𝑖𝑡𝑒𝑟 𝑜𝑓 𝑣𝑖𝑟𝑎𝑙 𝑖𝑛𝑜𝑐𝑢𝑙𝑢𝑚 (

Human SERT (hSERT)
Expression of human SERT- Tetracycline inducible stably expressing hSERT HEK293 cell
line was kindly provided by Dr. Hidehito Takayama at Biotechnology Laboratory in
Yokohama Japan. This cell line was suspended, inoculated, and grown in complete growth
media (Dulbecco’s Modified Eagle Medium (DMEM) supplemented with 10% FBS, 1%
Penicillin-Streptomycin-Glutamine (PSQ), 100 ug/ml zeocin antibiotic). Cells grown in 75
cm2 flask and stored in a 37°C, and 5% CO2 incubator for 48 hours. Next, the cells washed
with Hank’s buffered salt solution (HBSS), the supernatant was removed, and the confluent
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cells were washed with 10 mL of HBSS. The cells were detached from the flask with 2 mL
of trypsin-EDTA, and once detached 8 mL of DMEM growth media was added to
inactivate the trypsin-EDTA. The cell suspension was transferred to a 15 mL Falcon tube
and centrifuged at 1000 g for 5 minutes. The supernatant was discarded, and the cell pellet
was resuspended in 10 mL of DMEM growth media and transferred to 10 cm diameter
tissue culturing plates, where the cells were grown for 3 days in a 37°C, and 5% CO2
incubator in preparation for tetracycline induction. At 90% confluence the media was
aspirated, and the cells were tetracycline induced in an induction medium containing
DMEM growth media supplemented with 10% FBS, PSQ, 1 ug/ml tetracycline. The cells
were grown at 37°C and 5% CO2 for 24 hours. Afterwards, the cells were centrifuged at
1000g for 5 minutes and the medium was completely removed. The cells were washed in
rinse buffer (137mM NaCl, 2.7mM KCl in PBS). Cells were transferred to 50 mL Falcon
tubes and centrifuged at 1,000g for 5 minutes and the supernatant was discarded to collect
cell pellet.
Purification- Cells were lysed by sonication (microtip set to max, 50% duty cycle, Branson
Sonifier 250, VWR) on ice, two times for 15 seconds with a 10 second break in between
to prevent the cells from over-heating, in a lysis buffer (10 mM Tris-HCl, 1 mM EDTA in
10 ml of deionized water) containing an anti-proteolytic cocktail (1.6 µunits/ml aprotinin,
100 µM phenylmethanesulfonyl fluoride (PMSF), 1 mM benzamidine, 100 µM
benzethonium chloride) to minimize protein degradation. Cell membranes containing
SERT were isolated by ultracentrifugation (65,000 rpm in a 70.1 Ti rotor for 30 minutes at
4°C). Cell pellets were washed and procedure was repeated a second time. SERT was
solubilized overnight at 4°C in 10 mL solubilization buffer (20 mM Tris-HCl pH 7.4, 500
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mM NaCl, 1 mM EDTA, 1 ml of glycerol, 1% digitonin detergent, and anti-proteolytic
cocktail). The solubilized SERT was ultra-centrifuged using the same parameters and the
supernatant was subjected to affinity chromatography using anti-FLAG antibody beads
(Anti-FLAG M2 affinity gel, product number A2220) by Sigma-Aldrich following the
manufacturer’s instructions. Briefly, 2 ml of resin was transferred to a sterile 15 mL Falcon
tube, centrifuged at 3,200 g for 2 minutes at 4°C. The supernatant was removed without
discarding any resin and the resin was washed twice with 10 mL of TSB buffer (50 mM
Tris HCl, 150 mM NaCl, pH 7.4). The solubilized SERT was then added to the resin and
incubated for 2 hours at 4°C with gentle agitation. The tube was centrifuged at 3,200 g for
2 minutes at 4°C and the supernatant was removed. The resin containing SERT was washed
twice with 8 mL of wash buffer (25 mM HEPES pH 7.4, 150 mM NaCl, 10% glycerol, 1%
digitonin) and centrifuged at 3,200 g for 2 minutes at 4°C. Next, 2 mL of elution buffer (25
mM HEPES pH 7.4, 150 mM NaCl, 10% glycerol, 1% digitonin, 250 ng/ul 3X FLAGpeptide) was added to the resin and incubated at room temperature for 30 with gentle
agitation. Finally, the tube was centrifuged at 3,200 g for 2 minutes at 4°C and the eluate
(purified SERT) was stored at -20°C.
Isolation of SERT was verified by western immunoblot analysis using anti-FLAG
antibody against FLAG-epitope tag. Protein samples were subjected to SDS-PAGE
electrophoresis (10% resolving, 5% stacking) and transferred to a nitrocellulose membrane
at 90 mA constant current overnight at 4°C. The membrane was treated with Odyssey
blocking buffer and incubated for 1 hour at room temperature with gentle agitation. Next,
the blocking buffer was discarded and replaced with a primary antibody (monoclonal
mouse ANTI-FLAG M2, Sigma-Aldrich) solution with a dilution of 1 µg/mL (5 mL
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blocking buffer, 0.1% Tween-20), the membrane was incubated for 2 hours at room
temperature. The membrane was washed 4 times with gentle agitation in wash buffer (PBS
with 0.1% Tween-20) for 5 minutes each. The membrane was incubated with a solution
containing secondary antibody (IR-conjugated 800 CW goat anti-mouse secondary
antibody with a dilution of 1:5,000) in PBS with 0.1% Tween-20 for 1 hour. The membrane
was again washed 4 times in wash buffer (PBS with 0.1% Tween-20) and scanned on an
Odyssey imager.
Lowry Assay- Protein concentration was determined via modified Lowry assay utilizing 120 µg/ml bovine serum albumin (BSA) standard curve in duplicates [174]. Protein samples
were prepared in duplicates. Precipitation was initiated by adding 150 μL of 1.0%
deoxycholate, vortexing, and resting at room temperature for 10 minutes. 0.1 mL of 72%
trichloroacetic acid was added, vortexed, and spun at 7000 g for 10 minutes. The samples
were aspirated and 0.2 mL of dH2O was added. 1.0 mL of a Modified Lowry reagent was
added to each sample, mixed, and incubated at room temperature for 10 minutes. 100 μL
of a 1X Folin-Ciocalteu reagent was added, vortexed, and incubated at room temperature
for 30 minutes. Addition of the 1X Folin-Ciocalteu reagent and the 30-minute incubation
period were done in the dark. Absorbances were recorded with a UV-Vis spectrophotometer
at 750 nm with BSA standards used to determine the protein concentration by performing
linear regression analysis on the standard curve.
Removal of affinity tag on hSERT- Removal of FLAG-tag was performed using ProTEV
Plus protease (Promega Cat# V6101). ProTEV Plus also contains an HQ tag located at the
N-terminus of the protein, which can be removed from the cleavage reaction on affinity
resins. The protease reaction was carried out by mixing the following in a 1.5mL centrifuge
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tube: 80 µg of hSERT with 20 µl of 20X ProTEV buffer, 4 µl of 100 mM DTT, 4 µl of
ProTEV Plus protease and autoclaved deionized water to a final volume of 400 µl. The
reaction was incubated at 30°C overnight. hSERT was isolated by affinity chromatography
in a nickel column using HIS-select nickel affinity gel (Sigma-Aldrich, Cat# P6611). 200
µl of HIS-select nickel affinity gel was added to a microcentrifuge tube and centrifuge for
30 seconds at 5,000 g. The supernatant was carefully removed and discarded. 800 µl of
equilibration buffer (50 mM sodium phosphate pH 8, and 0.3 M sodium chloride) was
added and mixed. The tube was centrifuged for 30 seconds at 5,000 g and the supernatant
was discarded. 400 µl of hSERT/protease solution was added to the column and gently
mixed for 2 minutes. ProTEV Plus protease binds to the nickel resin. The mixture was
centrifuged for 30 seconds at 5,000 g and the supernatant containing eluted hSERT was
collected. The affinity gel column was washed 2 times with 500 µl of equilibration buffer,
the tube was gently mixed for 10 seconds, then centrifuged for 30 seconds at 5,000 g and
the supernatant was saved. Next 200 µl of elution buffer (equilibration buffer with addition
of 250 mM imidazole) was added to the tube and centrifuged for 30 seconds at 5,000 g.
The elution step was repeated a second time with another 200 µl of elution buffer to
completely remove the protease from the nickel resin.
Reconstitution and addition and photo-crosslinking of pacFA-18:1 PC to rSERT or
hSERT- In studies examining crosslinking with photolabeled PC analogs, the addition of
the pacFA-18:1 PC analog took place during reconstitution into lipid vesicles. Briefly, 100
µL of SERT was sonicated in 0.5 ml of lipid solution containing 1.5 mg/ml of 90% plant
PC (95% phosphatidylcholine purity), 10% egg PC (60% phosphatidylcholine purity) and
0.004 mg/mL of pacFA-18:1 PC (Avanti) on ice. Samples were then injected into a dialysis
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cassette (3500 MW cutoff, Thermo Scientific). The cassettes were incubated at 4°C with
gentle spinning three times overnight, in excess 25 mM potassium phosphate buffer, pH
7.4. Final reconstituted protein was harvested and suspended in potassium phosphate buffer
(25 mM, pH 7.4).
Agonist crosslinking studies- The fluoxetine analog was kindly provided by Dr. Lapinsky
at Duquesne University Pharmacy Department. SERT (100 µL) was transferred to a sterile
non-stick 1.5 mL centrifuge tube and mixed with 1 µL of 100 mM fluoxetine analog stock
in DMSO. The mixture was incubated on ice for 1 hour in the dark to allow for the
fluoxetine analog to bind to SERT. Non-specific crosslink was then induced by
photoactivation. The mixture was transferred to a quartz cuvette and exposed to a 420 W
Hg Arc lamp (Newport Model 97435-1000-1, 260-320 nm) on ice for 4 sessions of 5
minutes with 5 minutes break of no UV exposure in between each session to prevent sample
warming. During UV exposure, the photoactivatable benzophenone moiety activates a
radical reaction and undergoes a hydrogen-radical abstraction with the nearest accessible
alpha carbon in the protein backbone, forming a covalent linkage.
In-gel trypsin digestion- Crosslinked samples were subjected to SDS-PAGE
electrophoresis (10% resolving, 5% stacking) separation. hSERT is approximately 70 kDa,
and appropriate gel plugs were excised. Gel plugs containing hSERT were washed with
50:50 absolute methanol: 50 mM ammonium bicarbonate 3 times for 15 minutes each with
gentle agitation (VWR Thermal Shake Touch, 800 rpm). Gel plugs were spun down, and
supernatant was removed. Gel plugs were dehydrated by adding 100 mM ammonium
bicarbonate in 50% acetonitrile and set at room temperature for at least 10 minutes. Once
gel plugs turned whitish, supernatant was removed, and gel plugs were dried in an
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Eppendorf 5301 Vacufuge Concentrator for 20 minutes. Proteolytic solution containing 10
µl of trypsin (Promega) at 20 µg/ml in 50 mM ammonium bicarbonate was added to each
gel plug and incubated on ice for 10 minutes, then incubated overnight with gentle shaking
(VWR Thermal Shake Touch, 800 rpm) at 37°C. Digested peptides were transferred to
VWR nonstick microcentrifuge tubes. Peptide fragments were extracted further by
incubating gel plugs for 30 minutes in 300 µl of elution solution (0.1% MS grade formic
acid in 50:50 acetonitrile/ultra-pure water) with gentle agitation at room temperature. The
supernatant was combined with initial supernatant. Peptides were dried in Eppendorf 5301
Vacufuge Concentrator.
Mass spectrometry- Dried digested peptides were resuspended in 50 µl of resuspension
solution (50:50 acetonitrile/ultra-pure water with 0.1% MS-grade formic acid). Mass
shifted peptides were found using electrospray ionization quadrupole time-of-flight mass
spectrometry (ESI-Q-TOF MS) and specific sites of covalent modification were identified
using MS/MS. ESI-Q-TOF measurements were taken using an Agilent 6530 Q-TOF MS
fitted with an Agilent HPLC-Chip II G424-62006 ProtID-Chip-150, comprised of a 40nL
enrichment column and a 75 µm x 150 mm separation column packed with Zorbax 300
SB-C18 5 µm material. Studies were run on a positive mode and internal standards
(1221.9906 and 299.2944) were provided by Agilent. Mobile phase solvents were Solvent
A (95% H2O, 5% acetonitrile, 0.1% formic acid) and Solvent B (95% acetonitrile, 5% H2O,
0.1% formic acid). The nanoflow elution gradient was developed as: 0.50 µL/min of
Solvent A (minute: percent A): 0.00: 95%; 4.00: 10%; 6.00: 70%; 9.00:50%; 11.50: 95%
and 13.00: 95%. MS data analysis was performed using Mass Hunter Qualitative analysis
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software 6.0 (Agilent) with 10 ppm error tolerance allowing for two miss cleavage sites
and possible mass shifts of the fluoxetine analog, oxidation, and acrylamide.
Mass shifted peptides found in MS analysis were run again targeting the specific
m/z ratio charge and retention time. Collision-induced dissociation (CID) was used for
MS/MS fragmentation following a linear increase in collision energy by m/z using the
equation: y=3.7x+2.5 and performed at ±0.2 min from the initial MS scan RT. MS/MS data
analysis was performed using Mass Hunter Qualitative analysis software 6.0 provided by
Agilent in conjunction with ProteinProspector v 5.22.1 available through the University of
California San Francisco.

2.2 Apo-state rSERT Structure
Molecular Cloning & Mutagenesis- Rat SERT (rSERT) cDNA in pBlueScript plasmid
(X8C) was kindly provided by Dr. Gary Rudnick from Yale University School of
Medicine. X8C was moved into the pFastBac transfer vector as described in section 2.1.
Single cysteine mutations were introduced at positions 109, 190, 232, 252, and 564 using
the QuickChange Lightning site-directed mutagenesis kit (Agilent). Forward and reverse
oligonucleotide primers (Eurofins Genomics) containing the desired Cys codon were
designed following suggested guidelines are presented in Table 2.1. The mutations were
introduced by PCR using the following conditions: 95°C for 1 minute, 95°C for 20 seconds,
62°C for 1 minute, 68°C for 7 minutes. This cycle was repeated 18 times. After Dpn1
digestion to remove parental plasmid, the DNA was transformed into XL-1 Blue competent
cells. Briefly, transformation was achieved by heat shock for 30 seconds at 42°C, 2 minutes
on ice, followed by recovery in 0.5 mL of SOC growth media for 1 hour with gentle shaking

37

at 37°C. Cells were plated overnight on LB-amp plates (0.1 mg/ml) of ampicillin antibiotic
at 37°C overnight. After overnight growth, single colonies were collected and grown
overnight in LB growth media containing 0.05 mg/ml of ampicillin with shake incubation
at 37°C and 225 rpm. After overnight growth, the plasmid DNA was extracted and purified
by miniprep using UltraClean Standard Mini Plasmid Prep Kit following the
manufacturer’s instructions. Successful introduction of cysteine codon was confirmed by
sequencing (GeneWiz).

Table 2.1 Oligonucletide primer pair sequences
Mutation

Oligonucleotide primer sequence

A109C

5’ CGGTTTCCTTACATATGCTACCAGAATGGCGGAGGG 3’

A109C-r

5’ CCCTCCGCCATTCTGGTAGCATATGTAAGGAAACCG 3’

S190C

5’ GCGCTCTACTACCTCATCTCCTGCCTCACGGACCGGCTGCCC 3’

S190C-r

5’ GGGCAGCCGGTCCGTGAGGCAGGAGATGAGGTAGTAGAGCGC 3’

Y232C

5’ CCCGCTGAGGAGTTCTGCTTGCGCCATGTCCTGCAG 3’

Y232C-r

5’ CTGCAGGACATGGCGCAAGCAGAACTCCTCAGCGGG 3’

S252C

5’ CAGGACCTGGGCACCATCTGCTGGCAGCTGACTCTCTGC 3’

S252C-r

5’ GCAGAGAGTCAGCTGCCAGCAGATGGTGCCCAGGTCCTG 3’

R564C

5’ GAGCCCACCCCAGCTATGCCTTTTCCAATACAACTATCCC 3’

R564C-r

5’ GGGATAGTTGTATTGGAAAAGGCATAGCTGGGGTGGGCTC 3’

Designed primer sequences forward and reverse. The yellow highlighted nucleotides code
for cysteine.
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Production of Recombinant Bacmid DNA- As described in section 2.1
rSERT Expression and Purification- As described in section 2.1
Reconstitution into lipid vesicles- As described in section 2.1 without the addition of
pacFA-18:1 PC analog.
Photo-crosslinking of MTS-benzophenone to rSERT- rSERT (100 uL) was mixed with 0.02
mg/ml of heterobifunctional methanethiolsulfonate benzophenone (MTS-benzophenone)
crosslinker (Toronto Research Chemicals) in DMSO. To ensure complete labeling excess
crosslinker was added (1:5 protein to crosslinker ratio). Protein-crosslinker mixture was
placed into quartz cuvettes and incubated on ice for an hour to allow for covalent binding
of the cysteine in rSERT to the MTS. Non-specific crosslink was then induced by
photoactivation. Cuvettes were exposed to a 420 W Hg Arc lamp (Newport Model 974351000-1, 260-320 nm) on ice for 4 sessions of 5 minutes with 5 minutes break of no UV
exposure in between each session to prevent sample warming. During UV exposure, the
benzophenone activates a radical reaction that undergoes a hydrogen radical abstraction
with the nearest accessible alpha carbon in the protein backbone.
In-gel trypsin/Glu-C digestion- Crosslinked rSERT was subjected to SDS-PAGE (10%
resolving, 5% stacking) electrophoresis to separate monomeric (~70 kDa) and oligomeric
(≥140 kDa) bands. Separate gel plugs were excised and washed with 50:50 absolute
methanol: 50 mM ammonium bicarbonate three times for 15 minutes each with gentle
agitation (VWR Thermal Shake Touch, 800 rpm). Gel plugs were spun down, and
supernatant was removed. 500 µl of 100 mM ammonium bicarbonate and 15 µl of 200 mM
DTT reducing agent was added to the gel plugs and incubated for 1 hour at 56°C to reduce
cysteine’s disulfide bonds into free sulfhydryl groups. Supernatant was replaced with 500
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µl of 100 mM ammonium bicarbonate and 15 µl of 200 mM iodoacetamide alkylation
reagent. Gel plugs were incubated for 1 hour at 37°C in the dark for alkylation of the
sulfhydryl groups to prevent disulfide bonds from reforming. Supernatant was removed,
and gel plugs were dehydrated by adding 100 mM ammonium bicarbonate in 50%
acetonitrile. Once gel plugs turned whitish, supernatant was removed, and gel plugs were
dried in an Eppendorf 5301Vacufuge Concentrator for 20 minutes. Proteolytic solution
containing 10 µl trypsin at 20 µg/ml, 10 µl Glu-C at 20 µg/ml in 50 mM ammonium
bicarbonate was added to the gel plugs and incubated on ice for 10 minutes. Next, 30 µl of
proteolytic solution was added to the gel plugs and incubated overnight at 37°C with gentle
agitation. Digested peptides were transferred to VWR nonstick microcentrifuge tubes.
Peptide fragments were extracted further by incubating gel plugs for 30 minutes in 300 µl
of elution solution (0.1% MS grade formic acid in 50:50 acetonitrile/ultra-pure water) with
gentle agitation at room temperature. The supernatant was combined with initial
supernatant. Peptides were dried in Eppendorf 5301 Vacufuge Concentrator.
Mass Spectrometry- All MS studies conducted as described previously in section 2.1.
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Chapter 3: SERT-Fluoxetine Interactions
3.1 Introduction
In serotonergic neurons, the end-product of the action potential is serotonin
exocytosis. In the synaptic cleft, serotonin binds to and activates post-synaptic ionotropic
and metabotropic receptors [175]. After this initial signal propagation, the relatively high
concentration of serotonin must be reduced to turn off the signal. SERT re-uptakes
serotonin, (5-hydoxytryptamine (5-HT)), from the synapse to the pre-synaptic cell. 5-HT
is then recycled into storage vesicles or inactivated by deamination by monoamine oxidase
[176]. Hence, SERT controls the concentration of serotonin in the synapse and affects the
magnitude and duration of the signaling [177]. This serotonergic signaling is affected when
serotonin concentration in the synapse is dysregulated leading to several neurological and
psychiatric problems such as anxiety, depression, obsessive compulsive disorder, posttraumatic stress and sleep problems, among other physiological problems [29, 37]. This
makes SERT is an important target for the development of antidepressants.
Tricyclic

antidepressants

(TCAs)

were

among

the

earliest

developed

antidepressants drugs. Although they may be effective, they are not selective for SERT and
can cause serious side effects such as seizures and cardiovascular problems [178]. Selective
serotonin reuptake inhibitors (SSRI) were discovered in the late 1960s and became widely
prescribed in the late 1980s [179] due to their relatively high selectivity for SERT and
limited off target receptors. However, despite this high selectivity they still bind to the
homologous transporters NET and DAT, although with much lower affinity[24, 41].

41

Figure 3.1 SERT transmembrane domains
Structure based on the citalopram bound crystal structure (PDB 5I71) viewed parallel to
the membrane with TM1-TM12 shown in blue, salmon, green, brown, red, yellow, cyan,
magenta, black, sky blue, orange, and hot pink, respectively. S1 and S2 binding pockets
shown as black and gold circles, respectively. Black lines indicate approximate location
of bilayer regions.

Two ligand-binding pockets are believed to exist: S1 which is located at the center
of the transmembrane domain, and S2 which lies in the extracellular vestibule above S1
[84] (Figure 3.1). The existence and role of the S2 binding pocket remains controversial,
as other studies suggest that the S1 site alone accounts for binding of serotonin and
inhibitors [180]. The first human SERT crystal structure was crystallized bound to
citalopram at both the S1 and S2 binding pockets [29]. However, in this and other highresolution studies many mutations and deletions of significant regions of the terminal tails
must be introduced for thermostability, and these reduce or eliminate the activity of the
transporter (see Table 1.2). In addition, these high-resolution structural studies use lipid
analogs and/or detergents as membrane mimetics and the structure of the transporter may
be affected by the lipid bilayer [173].
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Membrane proteins are greatly affected by lipid composition. A study by Magnany
et al. showed that SERT associates with lipid rafts and that disaggregation of lipids rafts
inhibits SERT activity [90]. In addition, interaction between phosphatidylinositol 4,5biphosphate (PIP2) and the N-terminus of DAT in vitro was observed in lipid binding
assays using a GST-fused hDAT N-terminus construct containing the first 64 amino acids
[91]. Constructs containing double mutations at positions K3A/K5A and K3N/K5N, show
to inhibit the ability of hDAT N-terminus to bind to PIP2, suggesting that this interaction
is driven by electrostatic forces.
To complement these studies, we conducted crosslinking studies of a
photoactivatable derivative of fluoxetine and full-length SERT reconstituted in lipid
vesicles. Crosslinking mass spectrometry has successfully been used to elucidate protein
structure, map protein-protein interactions and to identify protein-drug interactions [96,
136, 156, 181-189]. For example, Yip et al. utilized a photolabeling approach coupled with
mass spectrometry to successfully identify propofol binding sites on mammalian GABA A
receptors [190]. In this study, SERT was purified from an inducible hSERT overexpressing
HEK293 cell line. This system has been shown to produce functional SERT protein [9].
Nolan et al. [52] showed that hSERT obtained from HEK293 cells maintains binding
affinity (Ki = 284 ± 66 nM) and a high substrate uptake inhibition potency (IC50 = 1167 ±
26 nM) when bound to tetrahydropyridinyl compound. Yarravarapu et al. [191] used
hSERT obtained from HEK293 cells to evaluate hSERT binding affinity to a (S)citalopram derivative containing a photoreactive benzophenone, and was shown to present
a high binding affinity (Ki = 0.16nM).
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In this study, we similarly investigate the binding of a fluoxetine analog (Figure
3.2) to SERT, but extend these studies to include bottom-up MS to identify the sites of
crosslinking. Tandem mass spectrometry provides high sensitivity and mass accuracy
allowing us to identify specific amino acid residues involved in crosslinking [192, 193].
This combined with the use of a photoreactive fluoxetine analog will provide further insight
into drug-SERT interactions without the need to make any mutation, truncation, or other
modification on SERT. Herein, we present fluoxetine-SERT binding sites using a complete
and functional hSERT.

Figure 3.2 Structure of fluoxetine analog
Red region shows fluoxetine, black region
shows photoactivatable benzophenone for
photocrosslinking.

Given that fluoxetine partitions in bilayers [194] and might interact non-specifically
with membrane proteins, control studies with photoactivatable phosphatidylcholine (PC)
derivative lipids were also conducted to map lipid accessible sites (Figure 3.2). Comparison
of crosslinks between hSERT-fluoxetine analog and hSERT-PC analog allowed us to
potentially distinguish non-specific and specific sites of interactions between fluoxetine
and SERT.

Figure 3.3 Structure of diazirine phosphatidylcholine analog
pacFA-18:1 PC contains a diazirine which serves for photoaffinity labeling.
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3.2 Hypothesis
Drug binding sites in SERT can obtained using MSMS studies on digested peptides
bound to fluoxetine analog.
3.3 Results
hSERT was purified via affinity chromatography using a FLAG-epitope on the Nterminus against anti-FLAG affinity beads. The FLAG-tag was later removed using
ProTEV Plus protease. After photocrosslinking to fluoxetine analog, hSERT was subjected
to SDS-PAGE electrophoresis, and a band at the 70 kDa region was isolated, assuring that
the analyzed protein was that of SERT only. Peptides are analyzed by mass spectrometry.
MS separates peptides by mass-to-charge and creates a unique spectrum of protein
fragments, this fingerprint can then be examined to identify peptides whose mass has been
shifted by the mass of the covalently-attached crosslinker.
MS studies were conducted in triplicates from 3 biological replicates, and percent
coverages ranged from 15%-35%. Given that peptide fragments can be modified at
multiple sites, isobaric precursor ions can be generated. To avoid difficulties in the
assignment of isobaric product ion scans, MSMS spectra are not averaged over time, but
are strictly matched by retention time to their precursor ion, as in-line liquid C18
chromatography allows for the separation of isobaric peptides via their different chemical
properties. CID fragmentation for a given peptide within a retention time window of ±0.2
minutes produced several product ion fragmentation spectra. Each spectrum was analyzed
individually to identify specific sites of photocrosslinking. A representative precursorproduct ion spectrum is shown in Figure 3.4.
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Mass to charge ratio (m/z)
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Mass to charge ratio (m/z)

Figure 3.4 Representative MS and MSMS spectrum of precursor and product ion
scan. (A). Complete MS ion chromatogram, encircled area indicates region where a
mass shifted peptide was observed at retention time 3.862 min (B). A precursor ion with
an m/z 703.8514 corresponding to doubly charged peptide 80ETWGKK85 mass shifted by
fluoxetine analog was identified (peak identified with a black arrow). (C) CID
fragmentation of this crosslinked precursor ion. Product ion fragments are labeled (A-D)
and specific site of crosslink is bolded and underlined.
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In the hSERT-fluoxetine analog study, crosslinking events were identified in the
N-terminus, TM2-TM3 intracellular (IC) loop, the extracellular (EC) loop between TM3TM4, the IC loop between TM4-TM5, the EC loop between TM7-TM8, TM12 and the Cterminus (Table 3.1). The fluoxetine analog contains a fairly long hydrophobic tail (~20Å)
therefore, it was possible to see crosslinks to the intracellular loops. These regions are
discussed in detail in the “Discussion” in section 3.4.

Table 3.1. hSERT-fluoxetine analog crosslinks
Peptide
80

ETWGKK85

153

235
273

391
597

Modification

KICPIFK159

HVLQIHR241

GVKTSGK279

NEDVSEVAK399

LIITPGTFKERIIK610

80-85

Fluox/ 80-85 Fluox, Oxi

153-159

Fluox/ 153-159 Fluox, Acryl
153-159
Fluox, Acryl
235-241
Fluox, Oxi/ 235-241 Fluox

273-279

Fluox, Acryl / 273-279 Fluox, Acryl
276-279
Fluox
392-399
Fluox

Structural Location
N-Terminus
TM2-TM3 IC
Loop/TM3
TM3-TM4 EC Loop
TM4-TM5 IC Loop
TM7-TM8 EC Loop

597-610

Fluox, Acryl / 608-610 Fluox
TM12/C-Terminus
597-605
Fluox
627
627-630
LNAV630
Fluox
C-Terminus
Identified mass-shifted peptides within 10 ppm error. Specific sites of covalent crosslink
identified via CID fragmentation analysis are bolded and underlined.
Sites of crosslinking were mapped onto a model of hSERT-citalopram crystal
structure (PDB#5I71) for visualization purposes (Figures 3.5-3.7).
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Figure 3.5 hSERT-fluoxetine
analog crosslinks.
Red regions indicate fluoxetine
crosslinks. Black lines indicate
approximate location of bilayer
regions.
Crosslinks are mapped on
structure of hSERT bound to
citalopram (PDB# 5I71) [1].
Not all crosslinking data can be
shown as some regions are
missing in the crystal structure.

In the hSERT-fluoxetine studies, the FLAG-tag located at the N-terminus was
cleaved off. However, in the rSERT (rat SERT) studies (Chapter 4) the FLAG-tag located
in the C-terminus was not removed due to missing cleavage site. Therefore, to test for
any possible artifacts attributable to the sites of chimeric tags, additional CX-MS studies
were conducted using baculovirus overexpression of rSERT. In the rSERT-fluoxetine
analog study, crosslinks corresponding to the following regions were found: N-terminus,
TM 2-TM 3 IC loop, TM 3-TM 4 EC loop, and TM 5-TM 6 EC loop (Table 3.2). In both
studies, we observed crosslinking to the N-terminus, TM 2-TM 3 IL, TM 3-TM 4 EL
however, no crosslinks to the C-teminus and TM 7-TM 8 EL were observed in the
rSERT-fluoxetine study.
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Table 3.2 rSERT-fluoxetine analog crosslinks
Peptide
11

VLSEAKDR18
154
IAPIFK159
235
HVLQIHQSK243
299
GATLPGAWR307

Modification
11-18

Fluox
Fluox
235-243
Fluox, Acry, Oxi
299-307
Fluox
154-159

Structural Location
N-Terminus
TM2-TM3 IC Loop/TM3
TM3-TM4 EC Loop
TM5-TM6 EC Loop

Identified mass-shifted peptides within 10 ppm. Specific sites of covalent crosslinks
identified via CID fragmentation analysis are bolded and underlined.

Figure 3.6 rSERTfluoxetine analog
crosslinks.
Red
regions
indicate
fluoxetine crosslinks. Black
lines indicate approximate
location of bilayer regions.
See Fig. 3.5 for analogous
details.

Fluoxetine can partition in the lipid bilayer [194-196] as well as neurotransmitters
including dopamine [197] and serotonin [198]. Hence, fluoxetine might interact nonspecifically with membrane proteins. Since these presumably low abundant non-specific
interactions might be detected by this highly sensitive MS approach, control studies with
photoactivatable lipids were also conducted to map lipid accessible sites. Here, both the
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fluoxetine analog and a phosphatidylcholine (PC) derivative were used. In the hSERTfluoxetine/PC study, we observed PC crosslinks to TM4-TM5 IC loop and on the rSERTfluoxetine/PC study we observed PC crosslinks to the N-terminus, TM3-TM4 EC loop,
TM4-TM5 IC loop, and TM5-TM6 EC loop (Table 3.3).

Table 3.3 SERT-PC analog crosslinks
Peptide
11
76

Modification

VLSEAKDR18

QGERETWGK

235

PC ++ / 17-18 PC, 2 Acry ++

84

243

HVLQIHQSK

273

11-18

GVKTSGK279

Structural Location

76-84
235-243
273-275

PC

N-Terminus

++

PC, Acry, Oxi ++

TM3-TM4 EC Loop

PC + / 273-275 PC, 2 Acry +/
PC ++ 276-279 PC, Acry ++
299-307
PC ++

TM4-TM5 IC Loop

273-275
299

GATLPGAWR307

TM5-TM6 EC Loop

Identified mass-shifted peptides within 10 ppm error. Specific sites of covalent crosslinks
identified via CID fragmentation analysis are bolded and underlined. + Indicates hSERT,
++
indicates rSERT

Figure 3.7 SERT-PC analog
crosslinks.
Blue regions indicate PC
crosslinks,
black
lines
indicate approximate location
of bilayer regions.
See Fig. 3.5 for analogous
details
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A

90°

B

Figure 3.8 Summary of SERT crosslinks to fluoxetine and PC analog
(A) Crosslinks illustrated using the citalopram-bound human crystal structure of hSERT
(PDB# 5I71). Red regions represent crosslink to fluoxetine analog, blue regions
represent crosslink to PC, purple represents crosslink to both fluoxetine and PC. (B)
Bead model of SERT crosslinks. Red regions represent crosslink to fluoxetine analog,
blue regions represent crosslink to PC, purple represents crosslink to both fluoxetine
and PC. Light grey indicates regions observed without the crosslinker, dark grey
indicates regions not observed.
Not all fluoxetine crosslinking data can be shown in (A) as some regions are missing in the crystal structure
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Crosslinks to regions located in the S1 and S2 binding pockets were observed.
However, given that the distance between S1 and S2 (13 Å) is shorter than the distance
between the crosslinking moiety and the drug itself (20 Å), the exact binding location of
the fluoxetine analog remained inconclusive. However, other novel results were observed.
Below are key points to take from the observed crosslinks; these points are explained in
more detail in the “Discussion” (Section 3.4).

Terminal tails appear to be closely associated with the membrane
Crosslinks to the terminal tails is interesting as they are missing from the crystal
structures. Both hSERT-fluoxetine and rSERT-fluoxetine studies showed crosslinks to
both the N-terminus and C-terminus, suggesting they are closely associated with the
membrane. The fluoxetine analog can only bind to either S1 or S2 binding pockets and as
mentioned earlier, S2 is located midway the bilayer and S1 is located just above S2. The
hydrophobic core of the lipid bilayer is approximately 30 Å thick while the hydrophilic
head group regions are approximately 15 Å each. Given that the photoactivatable moiety
can crosslink to amino acids within a distance of 20 Å, it is possible for the analog to bind
to S1 or S2, and crosslink to regions of the protein near the membrane facing the
intracellular side. This observation was also found in another study done in our laboratory
by Andrew DeMarco, where he identified hSERT crosslinks to azi-cholesterol. In addition,
crosslinks to the terminal tails were also observed in the protein-protein study in chapter 4.
The fact that the SERT-fluoxetine study, the protein-protein study and the SERT-azi
cholesterol study all showed crosslinks to the terminal tails show that there is consistency
and support this observation.
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A region of extracellular loop 2 is closely associated with the membrane
The EC 2 is the largest loop, and its structure is unknown. Fluoxetine and PC
crosslink to peptide

235

HVLQIHQSK243 suggests there is non-specific binding, and that

this is a lipid accessible region. Crosslinking to this peptide was also observed in our
laboratory by DeMarco et al. in analogous studies using photoactivatable cholesterol [199].
Further supporting that this region of the loop comes in proximity with the membrane.
The lower region of TM12 shows movements/rearrangement
Unlike LeuT but reminiscent of DAT, SERT has a kink in TM12. This kink is
halfway across the membrane and angled ~20 degrees away from the protein [21]. The
functionality of this kink is unknown, but studies have suggested that there is mobility in
the lower region of TM12. Hydrogen deuterium exchange studies by Moller et al. [177]
showed that 5-HT induces changes in the dynamics of hSERT in regions of EL4 and TM12.
In this study, we observed crosslinking to 599ITPGTFKERIIK610 located in the lower region
of TM12. The fluoxetine analog used in this study has a distance of ~20Å between the
crosslinking moiety and the drug itself, limiting crosslinking to regions within this range.
PyMOL visualization software analysis was used to measure distances between position
597 and Asp98 in subsite A, Tyr176 in subsite B, and Thr497 in subsite C, using the
citalopram bound SERT crystal structure (PDB # 5I71). The distances found were 43.6 Å,
39.7 Å, 31.5 Å, respectively. This observation suggests that there is movement in the apo
form not observed in the drug bound crystal structure. One possibility is that when
fluoxetine is bound, the lower region of TM12 tilts inward, hence becoming available for
crosslink.
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Other crosslinks are consistent with the literature. PC crosslinks in TM4-TM5 IL
and TM5-TM6 EL overlap with known cholesterol binding sites known as cholesterol
recognition/interaction amino acid consensus sequence or CRAC and its mirror motif,
CARC [200]. Mutagenesis studies by Laursen et al. [201] show that there is cholesterol
binding to TM1 and TM5 (adjacent to TM4-TM5 IL and TM5-TM6 EL), supporting the
observation that those regions are in proximity with the membrane. This observation
suggest that this study does not produce random crosslinks. Instead, it shows that CX-MS
is a powerful tool that can provide accurate results which can be used as a complement to
other biophysical methods to provide structure information of regions not available in other
high-resolution methods.
Some sites of crosslinking are not shown as they are missing from the model such
as the terminal tails. Crosslinks to areas not seen in the crystal structure show that current
models need refinements and that those regions play a key role and thus need to be
considered when studying SERT and its binding sites. The observation also highlights the
utility of CX-MS based approach which can provide local structure information of regions
not available in other high-resolution structures.

3.4 Discussion
As the cases of anxiety and depression continue to grow [202], the need to
understand how antidepressants act is much greater. It is crucial to understand the structural
and mechanistic details underlying the binding process to develop new, improved, and
efficient antidepressants. The x-ray crystallography and cryo-EM structures of SERT offer
great insight into ligand interaction sites. However, they lack important regions that are
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known to play key roles in activity such as the terminal tails. In addition, these structures
contain many mutations needed to achieve thermostability. In this study, we identify sites
of interaction of SERT with a photoactivatable fluoxetine analog in the presence of an
intact bilayer as a unique complement to current high-resolution structures.
The presence of crosslinking sites on the periphery of the transporter near the lipid
accessible surface raised concerns whether these sites might be due to non-specific
interactions due to the partitioning of fluoxetine analog in the reconstituted bilayer. It has
been reported that many neurotransmitters and drugs, including SSRIs, partition in the
bilayer [194-198]. To control for this, parallel studies were conducted with photoactivable
PC included in the composition of the vesicles.
The PC analog showed crosslinks to peptide

235

HVLQIHQSK243 in TM3-TM4

extracellular loop overlapping with regions of labeling in fluoxetine-hSERT studies (See
Tables 3.1-3.3). The TM3-TM4 loop is the largest extracellular loop whose structure is not
fully resolved as this loop is often truncated and mutated for thermostability in
crystallographic and cryo-EM studies of SERT and other MATs. We propose that the
fluoxetine-crosslinks that overlap with the PC-crosslinks observed in these CXMS studies,
might be due to non-specific lipid binding regions (See Tables 3.1-3.3). Given the
sensitivity of the MS platform, it would not be unexpected to see low frequency
crosslinking events. Interestingly, this same region of SERT was found to crosslink with
azi-cholesterol in previous studies conducted in our laboratory [199]. The two observations
suggest that this region is associating with the bilayer and represents a step towards
understanding the structure/function of this loop. PC-crosslinks were also observed to
273

GVKTSGK279 in IL2 and 299GATLPGAWR307 in EL3. These peptides also crosslinked
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with azi-cholesterol, further supporting the idea that these regions are also associating with
the bilayer and are being labeled non-specifically.
The PC crosslinks to the N-terminus at

78

ERETWGK84 and

11

VLSEAKDR18

suggest that the crosslink observed between fluoxetine and hSERT to the N-terminus is
also a nonspecific lipid binding site. Interestingly,

78

ERETWGK84 also crosslinked to

cholesterol in studies by DeMarco et al. [199]. This observation is interesting, as the Nterminus is believed to interact with phosphatidylinositol 4,5-bisphosphate (PIP2) lipids
[165], and this interaction has been shown to be prerequisite for amphetamines action on
SERT [203]. It is interesting to note that the PC crosslinked regions at 11VLSEAKDR18 in
the N-terminus and the

276

TSGK279 in the TM4-TM5 intracellular loop contain sites of

phosphorylation (Ser 13, Ser 277) [204]. This observation suggests the possibility that this
lipid interaction and its electrostatics may result in remodeling of the region upon
phosphorylation.
In our study we observed novel crosslinks as well as crosslinks consistent with
known structure information of SERT. The fluoxetine crosslinks to peptide

154

ICPI157

which is in the intracellular loop between TM2-TM3 and a portion of TM3, is consistent
with a section of the central binding site which according to Coleman et al. [1] is defined
to reside in TM1, TM3, TM6, TM8, and TM10. Fluoxetine crosslinking was also observed
to EL4 (TM7-TM8 extracellular loop), specifically 391NEDVS395. This is consistent with a
section of the allosteric binding site which resides in TM1, TM6, TM10, TM11, EL4 and
EL6 [1]. Fluoxetine analog crosslinks were also observed to EL2. EL2 participates in
extensive interactions with EL4 and EL6 and together they sculpt a portion of the allosteric
site [1]. We did not observed crosslinks to EL6 and the other regions that compose the
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allosteric and central binding sites. However, we note that the percent coverage was ~35%,
so negative results such as the absence of mass-shifted peptides detected cannot be
interpreted.
The crosslinks to the N and C-termini regions were surprising as their observance
suggests that these regions, absent from known structures and often drawn as intracellular
loops in schematics of the transporter, are closely associated with the membrane. This is of
special interest since these regions are known to be physiologically important in activity
[7, 166-169]. Sucic et al. found that the N-terminal of SERT can be found tethered in the
membrane [166] and other studies have suggested a close interaction of the N-terminus
with the membrane in hDAT [164]. Surprisingly, not only did we observe crosslinking to
the N-terminus but also the C-terminus, thus suggesting that regions in both termini may
be associated with the membrane in the apo structure. This observation questions the
accuracy of the SERT models currently used. In other corroborating studies conducted in
our lab by DeMarco et al., the terminal tails were also crosslinked by azi-cholesterol [199]
suggesting that these regions of the transporter are closely associated with the membrane.
The fluoxetine-hSERT crosslink to peptide

599

ITPGTFK605 in the lower region of

TM12 was unique. TM12 has a kink at the center causing the lower half to turn away from
the transporter, and it is conserved among hDAT, hNET and hSERT [21, 151]. The role of
TM12 is unclear, simulations studies suggest that it plays a role in dimerization [205],
however SERT structure has not been captured in an oligomeric state. HDX-MS studies on
dDAT suggest that TM12 may play a role in transport mechanism and/or regulation of
transporter activity [206]. The crystal structure of dDAT bound to antidepressant
nortriptyline and locked in an outward open conformation shows that the lower region of
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TM12 is approximately angled ~20 degrees away from TM12 of LeuT [21]. An x-ray
crystallography study of hSERT bound to varying antidepressants revealed that though
they all stabilize SERT in an outward-open conformation, some residues can adopt
different conformations to mediate selectivity [30]. Furthermore HDX-MS studies on
hSERT detected differences between 5-HT and K+ bound states in the lower region of
TM12 [177], suggesting movement on TM12 during transport. In the citalopram-bound
structure [1] distances between position 597 in the lower region of TM12 and position 98
in subsite A, position 497 in subsite C and position 176 in subsite B that constitute the S1
site located at the center of the transmembrane domain were 43.6 Å, 31.5 Å, and 38.7 Å,
respectively. S2 is located above S1, therefore the distance between any amino acid within
S2 and position 597 is even longer. For the 20 Å long crosslinker to crosslink to the lower
region of TM12, this region had to come into proximity. We propose that this region is
dynamic and is oriented differently in the apo state of the transporter.
The crosslinks that align with known information about SERT structure and the
novel crosslinks were very promising. However, we could not determine the exact binding
site of fluoxetine due to the long distance between the photoactivatable moiety and the
fluoxetine moiety. The distance between the allosteric and central binding sites is
approximately 13 Å [1], and the distance between the benzophenone and the fluoxetine
active site is approximately 20 Å. Hence, not only can we observe the regions lining the
central and allosteric sites, but we can also observe regions located even further from the
binding site. As a result, the exact binding location of the fluoxetine analog remained
inconclusive.
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Overall, this study highlights the power of CX-MS to identify crosslinks directly
and sensitivity on SERT. The fluoxetine analog showed to be an innovative approach and
although we could not determine the exact binding location of fluoxetine, we were able to
provide new information about SERT structure which can aid in expanding our current
understanding of SERT. For instance, we were able to identify lipid accessible sites which
are probably assisting in protein stabilization. We were able to shine light into regions that
may be associating with the membrane bilayer including regions, including the terminal
tails which are not visible in other high-resolution structures. In addition, we were able to
shine light into a possible role of TM12.
This approach is particularly advantageous in that it allows the studies to be
performed in a complete and functional SERT without any mutations, truncations, or
deletions. The results presented herein give an insight into local structure of protein regions
that are not available in other high-resolution structures and serves as a unique compliment
to current structures.
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Chapter 4: Apo-state SERT Structure
4.1 Introduction
Currently there is a wealth of high-resolution structures of SERT and other NSS
members available from crystallographic and cryo-EM studies [1, 30, 32, 33]. While these
studies provide tremendous insights into the structure of NSS members, these static images
have caveats in that the transporters are typically mutagenized for thermostability to reduce
sample heterogeneity and often have truncations of significant regions. Often such
alterations cause a loss of activity and/or binding affinity. As a result, many of today’s
available models are of inactive protein. In addition, these studies are also conducted in
membrane-mimetic environments and the structure of the transporter may be affected by
the lipid bilayer [173]. Multiple studies have shown evidence of lipid interactions with
SERT. Such as the necessity of lipid rafts in SERT’s activity [90] and the suggested
interactions between PIP2 lipids with the terminal tails [91]. Furthermore, lipid composition
is of great interest for its role on oligomeric state. There is growing evidence that SERT
forms a broad distribution of oligomeric states ranging from monomers up to pentamers
[92, 93]. Thus, it is essential to conduct studies of full-length SERT in a physiologicallyrelevant membrane to fully understand SERT structure and function.
A novel approach to assess complete structural information is by coupling chemical
crosslinking with mass spectrometry. Crosslinking mass spectrometry (CX-MS) studies do
not require truncations, allowing us to potentially identify distance constraints and generate
refined models of the entire functional transporter. CX-MS makes it possible to investigate
local structure of protein regions that are not available in other high-resolution structures.
CX-MS has been widely used to elucidate protein structure and to identify binding sites.
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For example, the structure of the mitochondrial prohibitin complex [182] and bovine serum
albumin [186] were investigated using lysine specific cross-linkers and MS to map spatial
distance constraints.
The loops and terminal tails of SERT play key functional roles in transport therefore
it is critical to refine current models and investigate these unmapped regions [163, 167].
The extracellular loops (EL) are not fully resolved in crystal structures yet are known to
play key roles in SERT activity. EL4 can modulate inhibitor binding and plays a crucial
role in controlling the conformational equilibrium of SERT [207]. Thus, to fully understand
SERT it is necessary to map its loops.
In this study, we probe the extracellular loops using a heterobifunctional
methanethiosulfonate (MTS) benzophenone reagent (Figure 4.1) to crosslink single
cysteine mutants to nearby amino acids and MS to identify the sites of crosslinked residues
and provide distance constraints. The photoactivatable benzophenone allows for nonspecific crosslinking, typically at backbone alpha C, within the crosslinking radius.
Figure 4.1 Structure of bifunctional
crosslinker
Benzophenone-4carboxamidoethyl methanethiosulfonate. It
includes a methanethiosulfonate moiety
shown in blue for SH coupling and a
photoactivatable benzophenone moiety
shown in red for photo-crosslinking.
The current SERT models available are those of hSERT bound to different SSRIs
which lock SERT in an outward-open conformation [29]. At present there is no information
about SERT in the apo state, and to fully understand SERT it is imperative to investigate
all its conformations during serotonin transport. This led us to investigate SERT in the apo
state. In this study, we specifically interrogate the topology of the EL1, 2 and 6. Given our
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need to systematically introduce specific single cysteine mutations and covalently bind the
given cysteine to a heterobifunctional crosslinker, single cysteines were introduced into a
Cys-null construct. In this construct, (provided by Dr. Rudnick at Yale University School
of Medicine) eight reduced cysteine residues were mutated –C15A, C21A, C109A, C147A,
C155A, C357I, C522S, and C622A– to produce an X8C rSERT. This construct was
reported to retain 32% of wild type transport activity and 56% of wild type binding activity
[95]. A109C was introduced to investigate topology of EL1. EL2 is the longest loop and
S190C, Y232C, and S252C were introduced separately, one at a time. Mutation R564C
was introduced to investigate EL6 (Figure 4.2).

Figure 4.2 SERT mutations and MS coverage for S252C
Mutations were introduced one at a time and are shown as yellow spheres. Pellet 3 trial 2
oligomer study for mutation S252C showed nearly 50% coverage. Blue regions represent
crosslink to MTS-benzophenone crosslinker, light grey represent regions observed without
the crosslinker, dark grey represent regions not observed.
Oligomerization of NSS proteins is believed to be crucial for their trafficking to the
membrane and substrate transport [208]. In numerous studies, DAT has been shown to
exist as a dimer or higher oligomer [152, 208-213] and there is growing evidence

62

suggesting oligomeric formation in SERT [92, 93, 214]. Liu et al. used MALDI-TOF MS
to identify and differentiate intra- from intermolecular Lys-Lys crosslinks in the
extracellular domain of the glycine receptor in comparative footprinting studies of
monomeric and oligomeric SDS-PAGE gel plugs [155]. Crosslinks observed in monomeric
bands must be intramolecular crosslinks, while crosslinks identified in studies of
oligomeric bands might be due to intra- or inter-molecular crosslinks. In this study, to
distinguish intermolecular from intramolecular crosslinking, comparative CX-MS
footprinting studies were conducted on monomeric and oligomeric bands.

4.2 Hypothesis
Structural information of SERT can be obtained by coupling photoaffinity
labeling and mass spectrometry.

4.3 Results
Single cysteine mutations were introduced in extracellular loops 1, 2, and 6 into a
cysteine-null rSERT cDNA (X8C). The commercially available bifunctional crosslinker
(benzophenone-4-carboxamidoethyl

methanethiosulfonate)

contains

a

methanethiosulfonate (MTS) moiety for SH coupling to the introduced cysteine, and a
photo-crosslinking benzophenone moiety for non-specific binding to amino acids within
20 Å. Upon photoactivation, SDS-PAGE gel-plus containing monomeric and oligomeric
peptides were isolated, and proteolyzed to differentiate intra from intermolecular
crosslinks. Mass shifted peptides containing the crosslinker mass were identified by
electrospray ionization quadrupole time-of-flight mass spectrometry (ESI-Q-TOF MS) and
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tandem MS studies identified specific sites of non-specific covalent attachment of the
photocrosslinker.
Initially, trypsin digests were performed, but these studies did not result in
acceptable levels of sequence coverage (only 5%-12% of rSERT was identified in control
and experimental samples). This is attributed to significantly large regions of the sequence
that do not contain arginine or lysine for trypsin digestion, with this being further
exacerbated by any missed cleavages. Therefore, a double digest was performed using
trypsin and Glu-C. The combination of the two produced percent coverages up to nearly
60%.
Pellets from 3 independent cell infections were prepared for each mutation, and
each pellet was analyzed in triplicates. Mass shifted peptides are only reported if observed
in at least 2 replicates. Given that peptide fragments can be modified at multiple sites,
isobaric precursor ions are expected. To correctly pair precursor and product ion scans to
allow for unambiguous product ion assignments, MSMS spectra are matched by retention
time to their precursor ion as in-line liquid chromatography allows for the separation of
isobaric peptides via their different chemical properties. CID fragmentation for a given
peptide within a retention time window of ±0.2 minutes produced several product ion
fragmentation spectra. Each spectrum was analyzed individually to identify specific sites
of crosslink. Sites of crosslinking were mapped using the crystal structure model of hSERT
bound to citalopram (PDB#5I71) for visualization purposes (Figures 4.3-4.7). All hSERT
crystal structures are bound to SSRIs that stabilize SERT in an outward-open conformation.
Our studies were performed in the apo state, therefore the spatial crosslinking mapped onto
the structure model may not represent the conformation of the transporter in its apo state.
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For instance, in the citalopram-bound structure, positions Y232C and R564C (see figure
4.3) might seem inaccessible from the TM1 region, but become accessible for crosslink in
the apo state.

Figure 4.3 Top-down view of SERT
Mutations A109C, S190C, Y232C,
S252C, and R564C are represented in
green, red, blue, yellow, and magenta
spheres, respectively. Black and gold
ovals represent location of S1 and S2
binding pockets, respectively.

The crosslinks observed for each introduced cysteine mutant are described below:

Mutation A109C- In the X8C plasmid, cysteine at position 109 was one of eight active
cysteine, hence it was replaced with alanine. Here it was returned it to active cysteine,
hence this mutation does not affect function. In the monomer study we observed
crosslinking to the N-terminus, TM2-TM3 IL, TM4-TM5 IL, TM5-TM6 EL, TM8-TM9
IL, and the C-terminus (Table 4.1). It is important to note that residues 20-37 in the Nterminus were observed in the oligomer only, this could suggest a N-terminus movement
upon dimerization of SERT. This observation agrees with previous studies which have
suggested that the N-terminus is flexible and that this flexibility is necessary for function
[91, 164-166]. On the other hand, it might be due to structure differences between the apo
state and the outward-open state.
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Mutation S190C- In the monomer study we observed crosslinking to the N-terminus, TM2TM3 IL TM3-TM4 EL, TM5-TM6 EL, TM8-TM9 IL, and the C-terminus (Table 4.2). No
unique crosslinks in the oligomer compared to the monomer were observed. This shows no
intermolecular crosslinks which could indicate that S190C is not within proximity of the
dimer interface.

Mutation Y232C- In the monomer study we observed crosslinking to the N-terminus, TM1,
TM2-TM3 IL, TM4-TM5 IL, TM5-TM6 EL, TM8-TM9 IL, and the C-terminus (Table
4.3). Residues 20-39 in the N-terminus were only observed in the oligomer crosslinks. This
observation also suggests slight movements in the N-terminus upon dimerization.

Mutation S252C- In the monomer study we observed crosslinking to the N-terminus, TM2TM3 IL, TM4-TM5 IL, TM5-TM6 EL, TM7-TM8 EL, TM8-TM9 IL, and the C-terminus
(Table 4.4). Crosslinks to the TM3-TM4 EL were unique to the oligomer suggesting it is
due to intermolecular crosslinks. This observation suggests that mutation S252C (located
near TM4) is close to the dimer interface. This agrees with previous studies in which
cysteine crosslinking experiments suggest that TM4 is involved in dimer formation in DAT
[152, 210]. Coleman et al. suggested that EL2 participates in interactions with EL4 and
EL6 and together sculpt a portion of the allosteric site [29]. There was no coverage to EL6,
hence we did not see crosslinks to this region (See Fig. 4.2). Interestingly, mutation S252C
is in EL2 and although we did not see crosslinking to EL6 we observed crosslinking in
both the monomer and dimer studies to EL4.
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Mutation R564C- In the monomer study we observed crosslinking to the N-terminal, TM1,
TM2-TM3 IL, TM3-TM4 EL, TM5-TM6 EL, TM8-TM9 IL, and the C-terminus (Table
4.5). No difference was observed between the monomer and the oligomer study, in other
words no indication of intermolecular crosslinks. This suggests that mutation R564C is
also not within proximity to the dimer interface.
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Table 4.1 A109C Crosslinks

Identified crosslinked peptides observed in mutation A109C. Peptides were observed
within 10ppm error. The superscript numbers in the “Peptide” column represent the
sequence position of the peptide. The underlined amino acids represent sits of crosslink.
Blue font represents crosslinks from the monomeric bands, red font represents crosslinks
from the oligomeric bands, purple font indicates crosslinks observed in both monomeric
and oligomeric bands. The “Oligomeric Crosslink” column shows whether the peptide is
an intermolecular or intramolecular crosslink. Peptides are defined as intermolecular if
only observed in oligomeric bands. The “n” column represents the number of trials the
peptide was observed in both dimer and monomeric studies.

Figure 4.4 A109C crosslinking studies
Yellow sphere represents site of C109
attachment and sites of crosslinking are
shown in blue. Residues 1-76 and 618630 are truncated. Black lines represent
location of lipid membrane head group
region.
Data is mapped on crystal structure of
hSERT bound to citalopram PDB# 5I71
[1]. Not all crosslinking data can be
shown as some regions are missing in the
crystal structure.

68

Table 4.2 S190C Crosslinks

Identified crosslinked peptides observed in mutation S190C. Description of columns
described in table 4.1.

Figure 4.5 S190C crosslinking studies
Yellow sphere represents site of C190
attachment and sites of crosslinking are
shown in blue. See Fig. 4.3 for analogous
details.
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Table 4.3 Y232C Crosslinks

Identified crosslinked peptides observed in mutation Y232C. Description of columns as
described in table 4.1.

Figure 4.6 Y232C crosslinking studies.
Yellow sphere represents site of C232
attachment and sites of crosslinking are
shown in blue. See Fig. 4.3 for
analogous details.
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Table 4.4 S252C Crosslinks

Identified crosslinked peptides observed in mutation S252C. Description of columns as
described in table 4.1.

Figure 4.7 S252C crosslinking data
Yellow sphere represents site of C252
attachment and sites of crosslinking
are shown in blue. See Fig. 4.3 for
analogous details.
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Table 4.5 R564C Crosslinks

Identified crosslinked peptides observed in mutation R564C. Description of columns as
described in table 4.1.

Figure 4.8 R564C crosslinking studies.
Yellow sphere represents site of C564
attachment and sites of crosslinking are
shown in blue. See Fig. 4.3 for analogous
details.
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Crosslinks from mutations V310C, L406C, and V489C in EL3, EL4, and EL5
respectively, are currently being analyzed by Warren Lowther in our laboratory. The
network of all crosslinks from all EL is needed to create a more complete set of distance
constraints and map a thorough analysis of the structure of all the EL. Although this report
lacks comprehensive crosslinking data from every loop, the resulting unique and
interesting observations to date assist in our understanding of SERT structure. Below are
key points to take from the observed crosslinks; these points are explained in more detail
in the “Discussion” (Section 4.4).

The N- and C- terminals are closely associated with the membrane.
Crosslinks were observed to both termini from every mutation located in EL1, EL2,
and EL6. This observation was also observed in azi-cholesterol crosslinks performed in
our laboratory by Andrew Demarco, and in the SERT-fluoxetine study in chapter 3. The
fact that this study, the SERT-fluoxetine study, and the SERT-azi cholesterol study all
showed crosslinks to the terminal tails show that there is consistency and support this
observation.
Regions within IL1, IL2 and IL4 are closely associated with the membrane.
Mutations Y232C and S252C showed crosslinks to the IL2, while all mutations
showed crosslinks to IL1 and IL4. Given that our crosslinker has a highly nonpolar
benzophenone there is a possibility for the crosslinker to travel into the hydrophobic acylchains in the lipid bilayer and crosslink to intracellular regions if they come into proximity.
Therefore, this observation suggests that regions of IL1, IL2, and IL4 are closely associated
with the membrane.
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Position S252 is located near the dimer interface.
Mutation S252C showed intermolecular crosslinks to region 231-243. Crosslinks
to this region was not observed in the monomeric crosslinks. The dimer interface has not
been elucidated and although more studies are needed to define this region, our results
show that position 252 and region 231-243 are located at or near the dimer interface.
There are slight movements in the N-terminus.
Mutations A109C and Y232C showed intermolecular crosslinks in the N-terminus.
In mutation A109C, we see intermolecular crosslinks to
intramolecular crosslinks to

11

21

AQ22,

29

K, and

32

P, and

VLSEAKDR18. These intermolecular crosslinks are

evidence of movements in different regions within the same peptide. This observation may
indicate slight changes due to dynamics. Similarly, in mutation Y232C, we observed
intermolecular crosslinks to
11

20

DAQE23 and

34

TADR37, and intramolecular crosslinks to

VLSEAK16.

4.4 Discussion
To fully understand SERT it is imperative to investigate all its conformations
during serotonin transport. In this study, we provide unique information about SERT
structure in the apo state, which has not been resolved to date, thus providing new structural
information. Investigating the apo state is crucial because it will help us understand where
allosteric changes occur as it transitions from resting state to an outward-open
conformation with the drug bound. In this study, not only do we provide structure
information in a new state to which little is known about, but we also present crosslinks to
regions that are currently not resolved in the SERT structure. Altogether, our results serve
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as a unique complement to high resolution structures and can enhance current models. This
might bring more insight into SERT’s mechanism, which is of utmost importance to the
refinement and improvement of therapeutics.
It is important to note that the observed crosslinks were mapped using the crystal
structure of SERT bound to citalopram, which as previously mentioned is missing the
terminal tails, was crystallized in a membrane mimetic environment, and is bound to the
drug and is locked in the outward-open state. We performed our studies in the apo state.
Hence, the images are not an absolute representation of SERT in the apo state. There could
be movements which allow for the crosslinker to crosslink to areas that would seem
inaccessible in the outward-open state but that become accessible for crosslink in the apo
state.
Given that we used lipid vesicles where voltage gradient cannot be controlled, one
might suggest that the crosslinker reached the intracellular regions due to the protein being
positioned in the reverse orientation, that is with the intracellular regions facing out.
However, regardless of orientation, the EL and IL are separated by a lipid bilayer whose
acyl chains are about 30 Å across. The crosslinker used in this study can crosslink to any
amino acid within approximately 20 Å, from the carbonyl carbon in the benzophenone to
the alpha carbon of the rSERT backbone.
Crosslinking to the intracellular region of the protein was unexpected. Interestingly
we saw crosslinks to the IL from all five cysteines introduced in the ELs. Since the
crosslinker contains a highly non-polar benzophenone moiety there is a possibility that it
can travel into the hydrophobic tail regions of the membrane, and crosslink to intracellular
regions within 20Å. On one hand, the crosslinks to the intracellular regions might suggest
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protein flexibility. Ryl et al. [215] used crosslinking mass spectrometry to identify
structural restraints in human mitochondria using a non-cleavable crosslinker
disuccinimidyl suberate. Ryl et al. proved that crosslinking mass spectrometry can generate
enough data to unravel protein structure by identifying hundreds of distance restraints
between protein residues and comparing them to protein data bank structures. Overall, they
obtained crosslinks consistent with protein data bank structures, but some crosslinks
suggest protein flexibility occurring in situ [215]. The influence that the phospholipid
bilayer has on the structure and function of membrane proteins is well established.
However, the role it plays on membrane protein flexibility is understudied. Lipids are not
rigid but highly deformable molecules, this gives the lipid bilayer fluidity, and it may give
SERT a level of flexibility. To our knowledge SERT flexibility within the lipid bilayer and
its exact impact on protein structure has not been studied.
IL crosslinks may also indicate that such regions of the intracellular loops come in
close contact with the membrane. Peptide
449

145

NGAISIWRK153 in IL1 and peptide

AVLDEFPHIW458 in IL4 crosslinked from all mutations, suggesting that these regions

are closely associated with the membrane. Crosslinks to peptide

275

KTSG278 in IL2 were

observed in mutations Y232C and S252C. Interestingly, this peptide also crosslinked to PC
using both hSERT and rSERT (chapter 3) and by azi-cholesterol in studies performed in
our laboratory by DeMarco et al. using hSERT [199]. This suggests that this region is
closely associated with the membrane.
The crosslinker can crosslink to any amino acid within approximately 20 Å, this
helps us map distance constraints. We propose that peptide 145NGAISIWRKIAPIFK159 in
IL1 and peptide

445

GVITAVLDEFPHIWAKRR462 in IL4 are within 20 Å from each
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mutation. Whereas peptide

273

GVKTSGK279 is 20 Å from mutations Y232C and S252C

and at a distance greater than 20 Å from mutations A109C, S190C and R564C. (See Figure
4.8).
299

Crosslinks

to

EL3

was

observed

in

all

mutations,

peptide

GATLPGAWRGVVFYLKPNWQK319 crosslinked to mutations A109C, S190C,

Y232C and S252C and peptide 308GVVFYLKPNWQK319 crosslinked to mutation R564C.
This suggests that this region of EL3 is accessible to the mutations introduced in EL1, EL2,
and EL6 and is within 20 Å from each mutation. Crosslinks to peptide
231

FYLRHVLQIHQSK243 in EL2 was observed in mutations S190C, S252C and R564C.

Hence this region of EL2 is within 20 Å of these mutations, no crosslinks were observed
to mutations A109C, Y232C suggesting this region of the EL2 is possibly further out at a
distance greater than 20 Å from mutations A109C and Y232C. Crosslinks to EL4 were
only observed in mutation S252C. (Figure 4.8)

A

B

Figure 4.9 Network of crosslinks to intracellular and extracellular loops
(A) Network of crosslinks to the extracellular loops. (B) Network of crosslinks to the
intracellular loops. Yellow ovals represent the mutations, dark blue boxes represent
extracellular loops, light blue boxes represent intracellular loops, lines represent crosslinks
within 20 Å.
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The crosslinks to the terminal tails question the accuracy of the SERT models
currently used. Our results suggest that both the N and C-termini are closely associated
with the membrane. This is of special interest since those regions are not refined in the
models yet are known to be physiologically important in activity [7, 166-169]. Sucic et al.
found that the N-terminal of SERT can be found tethered in the membrane [166] and other
studies have suggested a close interaction of the N-terminus with the membrane in hDAT
[164]. Interestingly, in all mutations we observe crosslink to or near position 13 in the Nterminus, Ser13 is a phosphorylation site [204]. Possibly this lipid interaction and its
electrostatics results in remodeling of the region upon phosphorylation and/or perhaps it is
required for protein stability. Surprisingly, not only did we observe crosslinking to the Nterminus but also the C-terminus, thus suggesting that both terminal tails can be found
associated with the membrane. This was also observed in the fluoxetine-SERT study in
chapter 3, and in corroborating studies conducted in our lab by DeMarco et al., where the
terminal tails were also crosslinked by azi-cholesterol [199]. Previous studies have
suggested that the N-terminal interacts with the membrane and that this interaction is
necessary for transport, but here we provide evidence that both may be associated with the
membrane. The exact role of the C-terminal is not fully known and there is still much to
learn about the C-terminus, but our observation is a step forward towards understanding
the structure of the C-terminus.
Other crosslinks to the N-terminus are evidence of potential subtle changes due to
dynamics. In mutation A109C, we see intermolecular crosslinks to
and intramolecular crosslinks to

11

21

AQ22, 29K, and 32P,

VLSEAKDR18. These intermolecular crosslinks are

evidence of movements in different regions within the same peptide. Similarly, in mutation
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Y232C, we observed intermolecular crosslinks to
intramolecular crosslinks to

11

20

DAQE23 and

34

TADR37, and

VLSEAK16. These are the first observations of dynamic

movements within the N-terminus.
SERT dimerization is still an area of investigation, but by comparing monomeric
and oligomeric crosslinks we were able to identify unique intermolecular crosslinks.
S252C showed intermolecular crosslinks to the EL2. This observation suggests that
position EL2-EL2 interactions occur across a dimer interface, placing both 252 and 231243 as close enough to crosslink intermolecularly. This observation is significant as
SERT’s dimerization interface has not been elucidated. Although, more studies are needed
to map the dimer interface more closely, these are the first observations of a direct
interaction between SERT monomers.
Altogether, this study provides novel SERT structure information and shows the
capability of CX-MS to map protein-protein interactions. This study also serves as a
platform for future studies of SERT in other conformational states which could shine a
light into SERT’s allostery. This would enhance our current understanding of SERT and
bring us closer to the development of improved therapeutics for not only depression but for
numerous other disorders associated with SERT. This study highlights the power of CXMS, it allows for insight into local structure of protein regions that are not available in other
high-resolution structures and thus serves as a unique complement to current structures.
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Chapter 5: Future Directions
This study successfully shows that CX-MS can accurately provide distance
constraints of the full-length transporter in a native-like lipid environment. This method
can produce a wealth of information to complement current structures and enhance today’s
understanding of SERT’s function and structure. Protein pellets containing single cysteine
mutations V310C in EL3, L406 in EL4, and V489C in EL5 were MS analyzed by former
undergraduate student Adam Gargano. The mass shifted peptides found will be targeted to
determine specific sites of crosslink. The network of crosslinks from all EL will help us
further map the structure of SERT by creating more distance constraints in every EL. This
will shine light to more regions that cannot be characterized using high-definition structural
tools such as x-ray crystallography due to the dynamic nature of the loops. Additionally,
the complete network of distance constraints could help us map the dimer interface. The
intermolecular crosslinks found in specific single cysteine mutants, and the lack of
intermolecular crosslinks in other mutants might help us identify the region where two
subunits come together.
In addition, to further characterize distance constrains, analogous crosslinking
studies can be performed on the same point mutations but using crosslinkers of varying
lengths. Increasing or decreasing the “diameter” of the area within crosslinking reach,
would allow us to restrict the number of nearby crosslinks and further refine distances
between residues.
Creating distance constraints of SERT at different conformational states would
provide insight into SERT’s allostery. Warren Lowther is currently conducting
crosslinking studies using the same point mutations as in this study but in the inward-facing
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conformational state that is stabilized by binding of ibogaine. Comparing his data with the
data reported herein, will shine light into peptide movements occurring between the two
states using full length SERT. This information can complement x-ray crystallography and
cryo-EM structures, and offer a better understanding of the mechanistic changes that occur
during transition between states.
Given that the peak intensities in mass spectrometry reflect the relative ionization
of the mass ions not their concentration, the relative abundance of the crosslinks cannot be
determined. Quantification of the crosslinks would differentiate high probability events
from low probability events, thus further refining protein-protein interactions. The Cascio
lab has developed a laser-induced fluorescence microfluidic platform to quantify mass
shifted peptides (Andrew Davic, PhD Thesis, 2018). This method has the potential to detect
ultra-trace amounts of sample using fluorescence detection. Microdroplets containing
peptides are formed within a polyurethane microfluidic chip. Peptides are fluorescently
tagged, and the resulting fluorescence response is directly proportional to sample
concentration.
Membrane composition is known to influence protein structure and function.
Phospholipids vary in tail length, degree of saturation and head groups all of which have
an effect on the physical properties of membranes [216]. Studies on the nicotinic
acetylcholine receptor (nAChR) show that there are differences in transport mechanism in
relationship with nAChR interactions with phosphatidyl choline (PC) and phosphatidic
acid (PA). This study was performed using PC lipids, potential crosslinking differences
could be detected by performing analogous studies in PA lipids. Hence, showing the effect
that different lipid compositions have on SERT structure.
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Appendix
MS studies from 3 independent sample preparations were run in triplicate. Mass
shifted peptides reported in tables 4.1-4.5 were only reported if observed in at least 2
replicates. Peptides were observed with varying modifications such as acrylamide,
oxidation and alkylation. Below are detailed versions of tables 4.1-4.5:
Table A.1: A109C Dimer Crosslinks

Identified mass-shifted peptides (within 10ppm error) observed in the dimer study in
mutation A109C shown in the left column. Specific sites of covalent crosslink identified
via CID fragmentation analysis are bolded and underlined. Boxed peptide was observed in
the dimer study only, thus suggest an intermolecular crosslink. Parenthesized numbers in
the “modifications” column represent the number of times a precursor ion was observed
with the given modification.
Table A.2: A109C Monomer Crosslinks

Identified mass-shifted peptides in the monomer study in mutation A109C. Description of
columns as described in table A.1.
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Table A.3: S190C Dimer Crosslinks

Identified mass-shifted peptides in the dimer study in mutation S190C. Description of
columns as described in table A.1.

Table A.4: S190C Monomer Crosslinks

Identified mass-shifted peptides in the monomer study in mutation S190C. Description of
columns as described in table A.1.
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Table A.5: Y232C Dimer Crosslinks

Identified mass-shifted peptides in the dimer study in mutation Y232C. Description of
columns as described in table A.1.

Table A.6: Y232C Monomer Crosslinks

Identified mass-shifted peptides in the monomer study in mutation Y232C. Description of
columns as described in table A.1.
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Table A.7: S252C Dimer Crosslinks

Identified mass-shifted peptides in the dimer study in mutation S252C. Description of
columns as described in table A.1.

Table A.8: S252C Monomer Crosslinks

Identified mass-shifted peptides in the monomer study in mutation S252C. Description of
columns as described in table A.1.
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Table A.9: R564C Dimer Crosslinks

Identified mass-shifted peptides in the dimer study in mutation R564C. Description of
columns as described in table A.1.
Table A.10: R564C Monomer Crosslinks

Identified mass-shifted peptides in the monomer study in mutation R564C. Description of
columns as described in table A.1.
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Each peptide reported in tables A1-A10, is the result of the analysis of multiple
spectras at different retention times. The following MSMS chromatograms illustrate the
fragmentation analysis performed in this study for peptide FPHIWAKRR in Y232C Dimer.
N1 Trial 1 Dimer

a4

y4

Figure A.1: ESI-QTOF-MSMS spectra of FPHIWAK crosslinked peptide at retention time 3.477.
The asterisk represents the precursor ion. The double charged ion was seen at m/z 611.2839 and
fragmented by CID. The fragmentation pattern is shown, with possible sites of crosslink in bold.
Red peak represents an internal fragment

b2

Figure A.2: ESI-QTOF-MSMS spectra of FPHIWAK crosslinked peptide at retention time 3.557.
Description same as in Figure A.1.
Final result reported as FPHIWAK
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N1 Trial 2 Dimer

y1

Figure A.3: ESI-QTOF-MSMS spectra of FPHIWAKRR crosslinked peptide at retention time
3.733. The asterisk represents the precursor ion. The double charged ion was seen at m/z 777.4138
and fragmented by CID. The fragmentation pattern is shown, with possible sites of crosslink in
bold. Peaks shown in red represent internal ions, blue peak represents a fragment of the crosslinker.

a2

y1

b5

Figure A.4: ESI-QTOF-MSMS spectra of FPHIWAKRR crosslinked peptide at retention time
3.822. Description same as in Figure A.3.
Final result reported as FPHIWAKRR
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N1 Trial 3

b4

Figure A.5: ESI-QTOF-MSMS spectra of FPHIWAK crosslinked peptide at retention time 3.47.
The asterisk represents the precursor ion. The double charged ion was seen at m/z 611.2855 and
fragmented by CID. The fragmentation pattern is shown, with possible sites of crosslink in bold.
Red peaks represent internal ions.

y1

a5

Figure A.6: ESI-QTOF-MSMS spectra of FPHIWAK crosslinked peptide at retention time 3.62.
Description same as in Figure A.5.
Final result reported as FPHIWAK
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N1 Trial 3

y3

b8

y5

Figure A.7: ESI-QTOF-MSMS spectra of FPHIWAKRR crosslinked peptide at retention time
3.735. The asterisk represents the precursor ion. The double charged ion was seen at m/z 777.4149
and fragmented by CID. The fragmentation pattern is shown, with possible sites of crosslink in
bold. Red peak represents an internal ion.

a7

Figure A.8: ESI-QTOF-MSMS spectra of FPHIWAKRR crosslinked peptide at retention time
3.873. Description same as in Figure A.7.
Final result reported as FPHIWAKRR
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N2 Trial 2

y1
b5

Figure A.9: ESI-QTOF-MSMS spectra of FPHIWAK crosslinked peptide at retention time 3.855.
The asterisk represents the precursor ion. The double charged ion was seen at m/z 698.3000 and
fragmented by CID. The fragmentation pattern is shown, with possible sites of crosslink in bold.
Red peaks represent internal ions

y5

Figure A.10: ESI-QTOF-MSMS spectra of FPHIWAK crosslinked peptide at retention time
4.035. Description same as in Figure A.9.
Final result reported as FPHIWAK
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N2 Trial 3

y8

Figure A.11: ESI-QTOF-MSMS spectra of FPHIWAKRR crosslinked peptide at retention time
3.765. The asterisk represents the precursor ion. The double charged ion was seen at m/z 777.4088
and fragmented by CID. The fragmentation pattern is shown, with possible sites of crosslink in
bold. Read peak represents an internal ion.

a3

Figure A.12: ESI-QTOF-MSMS spectra of FPHIWAKRR crosslinked peptide at retention time
3.796. Description same as in Figure A.11.
Final result reported as FPHIWAKRR
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N3 Trial 1

y7

Figure A.13: ESI-QTOF-MSMS spectra of FPHIWAKRR crosslinked peptide at retention time
3.385. The asterisk represents the precursor ion. The double charged ion was seen at m/z 854.3923
and fragmented by CID. The fragmentation pattern is shown, with possible sites of crosslink in
bold. Red peaks represent internal ions, blue peak represents a fragment on the crosslinker.

b8

Figure A.14: ESI-QTOF-MSMS spectra of FPHIWAKRR crosslinked peptide at retention time
3.518. Description same as in Figure A.13.
Final result reported as FPHIWAKRR
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N3 Trial 2

y2

Figure A.15: ESI-QTOF-MSMS spectra of FPHIWAKR crosslinked peptide at retention time
3.445. The asterisk represents the precursor ion. The triply charged ion was seen at m/z 524.5932
and fragmented by CID. The fragmentation pattern is shown, with possible sites of crosslink in
bold. Red peaks represent internal ions.

a5

Figure A.16: ESI-QTOF-MSMS spectra of FPHIWAKR crosslinked peptide at retention time
3.557. Description same as in Figure A.15.
Final result reported as FPHIWAKR
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N3 Trial 3

y4

Figure A.17: ESI-QTOF-MSMS spectra of FPHIWAKR crosslinked peptide at retention time 3.6.
The asterisk represents the precursor ion. The double charged ion was seen at m/z 699.3506 and
fragmented by CID. The fragmentation pattern is shown, with possible sites of crosslink in bold.
Red peaks represent internal ions.

a5

Figure A.18: ESI-QTOF-MSMS spectra of FPHIWAKR crosslinked peptide at retention time
3.741. Description same as in Figure A.17.
Final result reported as FPHIWAKR
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N3 Trial 3

b8

Figure A.19: ESI-QTOF-MSMS spectra of FPHIWAKRR crosslinked peptide at retention time
3.483. The asterisk represents the precursor ion. The double charged ion was seen at m/z 854.3964
and fragmented by CID. The fragmentation pattern is shown, with possible sites of crosslink in
bold. Red peaks represent internal ions.

y1

Figure A.20: ESI-QTOF-MSMS spectra of FPHIWAKRR crosslinked peptide at retention time
3.515. Description same as in Figure A.19.
Final result reported as FPHIWAKRR
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Internal ions were observed in most spectras. They result from subsequent
collisions and continuing absorption of energy by “y” and “b” ions after the first bond
breakage. Typically, under CID “a”, “b” and “y” ions are produced. However, a CID
fragmentation study by Khatun et al. showed that high energy CID can produce a, x, c and
z ions [217]. In this study, we observed immonium ions and internal ions produced by the
neutral loss of water or ammonia. As well as unlikely internal ions but which were possible
due to high energy CID, as described by Khatun et al. These internal ions have been
reported before [217, 218] and a list of all internal ions found are reported in table A.11.

Table A.11: Internal ion fragments
Internal Ion Fragment

Theoretical
m/z
129.102788

Observed
m/z
129.9614

Retention
Time
N1T1
3.477

374.219215

374.2468

N1T1

3.557

101.107873

102.0535

N1T2

3.733

111.079647

112.0781
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Trial

120.081324

120.0737

133.043559

133.0591

343.213401

343.1615

854.504104

854.4149

120.081324

120.0831

133.043559

133.0899

148.076239

148.0589

Fragment of XL

Fragment of XL
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N1T2

3.822

200.139902

201.1214

230.129337

231.0969

438.237939

438.2301

481.280138

481.1914

536.298528

537.3385

854.504104

854.4052

127

120.081324

120.0819

N1T3

3.47

225.135151

225.1343

246.136828

247.1502

N1T3

3.735

315.225697

316.2586

N1T3

3.873

237.135151

238.1473

N2T2

3.855

454.232854

455.1620

128

486.362859

487.2764

N2T3

3.765

443.32066

443.2338

N2T3

3.796

785.526236

785.6547

432.263108

432.7257

N3T1

3.385

959.572535

959.6840

N3T1

3.385

673.349578

674.3772

N3T1

3.518

120.081324

120.0783

N3T2

3.445

129

431.24405

432.2861

111.079647

111.0598

130.121846

130.0800

133.043559

133.0854

502.281164

503.2371

120.081324

120.0774

172.144987

172.0950

N3T2

3.557

N3T3

3.6

Fragment of XL

130

200.139902

200.1357

229.202836

229.1299

133.043559

133.0860

172.144987

172.0994

252.158626

253.1988

230.129337

230.1102

N3T3

3.741

N3T3

3.483

Fragment of XL

131

508.303613

508.2806

356.20865

356.3787

438.237939

438.2387

536.298528

536.1580

607.335642

607.1895

830.458514

830.4098

N3T3

3.515

1066.58584 1066.3902

Internal ion fragments observed in chromatograms A.1-A.20 from peptide
FPHIWAKRR (at times observed as FPHIWAKR or FPHIWAK due to miss
cleavages) for the dimer study on mutation Y232C.
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